<!DOCTYPE html>
<html class="client-nojs" lang="en" dir="ltr">
<head>
<meta charset="UTF-8"/>
<title>Gilead Sciences - Wikipedia</title>
<script>document.documentElement.className="client-js";RLCONF={"wgBreakFrames":!1,"wgSeparatorTransformTable":["",""],"wgDigitTransformTable":["",""],"wgDefaultDateFormat":"dmy","wgMonthNames":["","January","February","March","April","May","June","July","August","September","October","November","December"],"wgRequestId":"XpoLyApAIEIAAKw-BmkAAACK","wgCSPNonce":!1,"wgCanonicalNamespace":"","wgCanonicalSpecialPageName":!1,"wgNamespaceNumber":0,"wgPageName":"Gilead_Sciences","wgTitle":"Gilead Sciences","wgCurRevisionId":951568940,"wgRevisionId":951568940,"wgArticleId":978997,"wgIsArticle":!0,"wgIsRedirect":!1,"wgAction":"view","wgUserName":null,"wgUserGroups":["*"],"wgPageContentLanguage":"en","wgPageContentModel":"wikitext","wgRelevantPageName":"Gilead_Sciences","wgRelevantArticleId":978997,"wgIsProbablyEditable":!0,"wgRelevantPageIsProbablyEditable":!0,"wgRestrictionEdit":[],"wgRestrictionMove":[],"wgMediaViewerOnClick":!0,"wgMediaViewerEnabledByDefault":!0,
"wgPopupsReferencePreviews":!1,"wgPopupsConflictsWithNavPopupGadget":!1,"wgVisualEditor":{"pageLanguageCode":"en","pageLanguageDir":"ltr","pageVariantFallbacks":"en"},"wgMFMode":"stable","wgMFAmc":!1,"wgMFAmcOutreachActive":!1,"wgMFAmcOutreachUserEligible":!1,"wgMFLazyLoadImages":!0,"wgMFDisplayWikibaseDescriptions":{"search":!0,"nearby":!0,"watchlist":!0,"tagline":!1},"wgMFIsPageContentModelEditable":!0,"wgWMESchemaEditAttemptStepOversample":!1,"wgULSCurrentAutonym":"English","wgNoticeProject":"wikipedia","wgWikibaseItemId":"Q663596","wgCentralAuthMobileDomain":!0,"wgEditSubmitButtonLabelPublish":!0,"wgMinervaPermissions":{"watch":!0,"talk":!1},"wgMinervaFeatures":{"beta":!1,"mobileOptionsLink":!0,"categories":!1,"pageIssues":!0,"talkAtTop":!1,"historyInPageActions":!1,"overflowSubmenu":!1,"tabsOnSpecials":!1,"personalMenu":!1,"mainMenuExpanded":!1,"simplifiedTalk":!0},"wgMinervaDownloadNamespaces":[0]};RLSTATE={
"site.styles":"ready","noscript":"ready","user.styles":"ready","user":"ready","user.options":"loading","ext.cite.styles":"ready","skins.minerva.base.styles":"ready","skins.minerva.content.styles":"ready","skins.minerva.content.styles.images":"ready","mediawiki.hlist":"ready","mediawiki.ui.icon":"ready","mediawiki.ui.button":"ready","skins.minerva.icons.wikimedia":"ready","skins.minerva.mainMenu.icons":"ready","skins.minerva.mainMenu.styles":"ready","mobile.init.styles":"ready","ext.wikimediaBadges":"ready"};RLPAGEMODULES=["site","mediawiki.page.startup","skins.minerva.options","skins.minerva.scripts","ext.gadget.switcher","ext.centralauth.centralautologin","ext.popups","mobile.init","ext.relatedArticles.readMore.bootstrap","ext.eventLogging","ext.wikimediaEvents","ext.navigationTiming","mw.externalguidance.init","ext.quicksurveys.init","ext.centralNotice.geoIP","ext.centralNotice.startUp"];</script>
<script>(RLQ=window.RLQ||[]).push(function(){mw.loader.implement("user.options@1hzgi",function($,jQuery,require,module){/*@nomin*/mw.user.tokens.set({"patrolToken":"+\\","watchToken":"+\\","csrfToken":"+\\"});
});});</script>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.cite.styles%7Cext.wikimediaBadges%7Cmediawiki.hlist%7Cmediawiki.ui.button%2Cicon%7Cmobile.init.styles%7Cskins.minerva.base.styles%7Cskins.minerva.content.styles%7Cskins.minerva.content.styles.images%7Cskins.minerva.icons.wikimedia%7Cskins.minerva.mainMenu.icons%2Cstyles&amp;only=styles&amp;skin=minerva"/>
<script async="" src="/w/load.php?lang=en&amp;modules=startup&amp;only=scripts&amp;raw=1&amp;skin=minerva&amp;target=mobile"></script>
<meta name="generator" content="MediaWiki 1.35.0-wmf.28"/>
<meta name="referrer" content="origin"/>
<meta name="referrer" content="origin-when-crossorigin"/>
<meta name="referrer" content="origin-when-cross-origin"/>
<meta name="theme-color" content="#eaecf0"/>
<meta name="viewport" content="initial-scale=1.0, user-scalable=yes, minimum-scale=0.25, maximum-scale=5.0, width=device-width"/>
<link rel="manifest" href="/w/api.php?action=webapp-manifest"/>
<link rel="alternate" type="application/x-wiki" title="Edit this page" href="/w/index.php?title=Gilead_Sciences&amp;action=edit"/>
<link rel="edit" title="Edit this page" href="/w/index.php?title=Gilead_Sciences&amp;action=edit"/>
<link rel="apple-touch-icon" href="/static/apple-touch/wikipedia.png"/>
<link rel="shortcut icon" href="/static/favicon/wikipedia.ico"/>
<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (en)"/>
<link rel="EditURI" type="application/rsd+xml" href="//en.wikipedia.org/w/api.php?action=rsd"/>
<link rel="license" href="//creativecommons.org/licenses/by-sa/3.0/"/>
<link rel="canonical" href="https://en.wikipedia.org/wiki/Gilead_Sciences"/>
<link rel="dns-prefetch" href="//login.wikimedia.org"/>
<link rel="dns-prefetch" href="//meta.wikimedia.org" />
<!--[if lt IE 9]><script src="/w/resources/lib/html5shiv/html5shiv.js"></script><![endif]-->
</head>
<body class="mediawiki ltr sitedir-ltr mw-hide-empty-elt ns-0 ns-subject mw-editable page-Gilead_Sciences rootpage-Gilead_Sciences stable issues-group-B skin-minerva action-view">
<div id="mw-mf-viewport">
	<div id="mw-mf-page-center">
		<a class="mw-mf-page-center__mask" href="#"></a>
		<header class="header-container header-chrome">
			<form class="header" action="/w/index.php" method="get">
				<nav class="navigation-drawer toggle-list view-border-box">
					<input type="checkbox" id="main-menu-input" class="toggle-list__checkbox" role="button" aria-labelledby="mw-mf-main-menu-button">
					<label for="main-menu-input" id="mw-mf-main-menu-button"
						class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-menu-base20 mw-ui-icon-flush-left toggle-list__toggle"
						title="Open main menu" data-event-name="ui.mainmenu">Open main menu</label>
					<div id="mw-mf-page-left" class="menu toggle-list__list view-border-box">
	<ul id="p-navigation">
			<li class="">
			    <a href="/wiki/Main_Page" class="mw-ui-icon mw-ui-icon-before mw-ui-icon-minerva-home" data-event-name="menu.home"><span>Home</span></a>
			</li>
			<li class="">
			    <a href="/wiki/Special:Random#/random" class="mw-ui-icon mw-ui-icon-before mw-ui-icon-minerva-die " data-event-name="menu.random"><span>Random</span></a>
			</li>
			<li class="jsonly">
			    <a href="/wiki/Special:Nearby" class="mw-ui-icon mw-ui-icon-before mw-ui-icon-minerva-mapPin nearby" data-event-name="menu.nearby"><span>Nearby</span></a>
			</li>
	</ul>
	<ul id="p-personal">
			<li class="">
			    <a href="/w/index.php?title=Special:UserLogin&amp;returnto=Gilead+Sciences" class="menu__item--login mw-ui-icon mw-ui-icon-before mw-ui-icon-minerva-logIn " data-event-name="menu.login"><span>Log in</span></a>
			</li>
	</ul>
	<ul id="pt-preferences">
			<li class="jsonly">
			    <a href="/w/index.php?title=Special:MobileOptions&amp;returnto=Gilead+Sciences" class="menu__item--settings mw-ui-icon mw-ui-icon-before mw-ui-icon-minerva-settings " data-event-name="menu.settings"><span>Settings</span></a>
			</li>
	</ul>
	<ul class="hlist">
			<li class="">
			    <a href="/wiki/Wikipedia:About" class="" data-event-name=""><span>About Wikipedia</span></a>
			</li>
			<li class="">
			    <a href="/wiki/Wikipedia:General_disclaimer" class="" data-event-name=""><span>Disclaimers</span></a>
			</li>
	</ul>
</div>

					<label class="main-menu-mask" for="main-menu-input"></label>
				</nav>
				<div class="branding-box">
					<a href="/wiki/Main_Page">
						<span><img src="/static/images/mobile/copyright/wikipedia-wordmark-en.svg" width="116" height="18" alt="Wikipedia"/></span>
						
					</a>
				</div>
				<div class="search-box">
					<input class="search mw-ui-background-icon-search skin-minerva-search-trigger" type="search" name="search" id="searchInput"
						autocomplete="off" placeholder="Search Wikipedia" aria-label="Search Wikipedia"
						value="">
				</div>
				<nav class="minerva-user-navigation" aria-label="User navigation">
					<div><button id="searchIcon" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-search-base20 skin-minerva-search-trigger" type="submit">Search</button></div>
					
				</nav>
			</form>
		</header>
		<main id="content" class="mw-body">
			<div class="banner-container">
			<div id="siteNotice"></div>
			</div>
			
			<div class="pre-content heading-holder">
				<div class="page-heading">
					<h1 id="section_0">Gilead Sciences</h1>
					<div class="tagline"></div>
				</div>
				<nav class="page-actions-menu">
	<ul id="page-actions" class="page-actions-menu__list">
		<li id="language-selector" class="page-actions-menu__list-item">
				<a id="" href="/wiki/Special:MobileLanguages/Gilead_Sciences" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-language-base20 mw-ui-icon-with-label-desktop language-selector"
					data-mw="interface"
					data-event-name="menu.languages" role="button" title="Language">Language</a>
		</li>
		<li id="page-actions-watch" class="page-actions-menu__list-item">
				<a id="ca-watch" href="/w/index.php?title=Special:UserLogin&amp;returnto=Gilead+Sciences" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-star-base20 mw-ui-icon-with-label-desktop watch-this-article mw-watchlink menu__item--page-actions-watch"
					data-mw="interface"
					data-event-name="menu.watch" role="button" title="Watch">Watch</a>
		</li>
		<li id="page-actions-edit" class="page-actions-menu__list-item">
				<a id="ca-edit" href="/w/index.php?title=Gilead_Sciences&amp;action=edit&amp;section=0" class="edit-page menu__item--page-actions-edit mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 mw-ui-icon-with-label-desktop"
					data-mw="interface"
					data-event-name="menu.edit" role="button" title="Edit the lead section of this page">Edit</a>
		</li>
	</ul>
</nav>
<!-- version 1.0.2 (change every time you update a partial) -->

				
				
				<div class="minerva__subtitle"></div>
			</div>
			
			<div id="bodyContent" class="content"><div id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><script>function mfTempOpenSection(id){var block=document.getElementById("mf-section-"+id);block.className+=" open-block";block.previousSibling.className+=" open-block";}</script><div class="mw-parser-output"><section class="mf-section-0" id="mf-section-0">
<p class="mw-empty-elt">
</p>
<p><b>Gilead Sciences, Inc.</b> <span class="rt-commentedText nowrap"><span class="IPA nopopups noexcerpt"><a href="/wiki/Help:IPA/English" title="Help:IPA/English">/<span style="border-bottom:1px dotted"><span title="/ˈ/: primary stress follows">ˈ</span><span title="/ɡ/: 'g' in 'guy'">ɡ</span><span title="/ɪ/: 'i' in 'kit'">ɪ</span><span title="'l' in 'lie'">l</span><span title="/i/: 'y' in 'happy'">i</span><span title="/ə/: 'a' in 'about'">ə</span><span title="'d' in 'dye'">d</span></span>/</a></span></span>, is an American <a href="/wiki/Biopharmaceutical" title="Biopharmaceutical">biopharmaceutical</a> company that researches, develops and commercializes <a href="/wiki/Pharmaceutical_drug" class="mw-redirect" title="Pharmaceutical drug">drugs</a>. The company focuses primarily on <a href="/wiki/Antiviral_drug" title="Antiviral drug">antiviral drugs</a> used in the treatment of <a href="/wiki/HIV" title="HIV">HIV</a>, <a href="/wiki/Hepatitis_B" title="Hepatitis B">hepatitis B</a>, <a href="/wiki/Hepatitis_C" title="Hepatitis C">hepatitis C</a>, and <a href="/wiki/Influenza" title="Influenza">influenza</a>, including <a href="/wiki/Harvoni" class="mw-redirect" title="Harvoni">Harvoni</a> and <a href="/wiki/Sovaldi" class="mw-redirect" title="Sovaldi">Sovaldi</a>.
</p><table class="infobox vcard" style="width:22em"><caption class="fn org">Gilead Sciences, Inc.</caption><tbody><tr><td colspan="2" class="logo" style="text-align:center"><a href="/wiki/File:Gilead_Sciences_Logo.svg" class="image"><img alt="Gilead Sciences Logo.svg" src="//upload.wikimedia.org/wikipedia/en/thumb/5/56/Gilead_Sciences_Logo.svg/250px-Gilead_Sciences_Logo.svg.png" decoding="async" width="250" height="70" srcset="//upload.wikimedia.org/wikipedia/en/thumb/5/56/Gilead_Sciences_Logo.svg/375px-Gilead_Sciences_Logo.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/5/56/Gilead_Sciences_Logo.svg/500px-Gilead_Sciences_Logo.svg.png 2x" data-file-width="157" data-file-height="44"></a></td></tr><tr><th scope="row" style="padding-right: 0.5em;"><div style="padding:0.1em 0;line-height:1.2em;"><a href="/wiki/List_of_legal_entity_types_by_country" title="List of legal entity types by country">Type</a></div></th><td class="category" style="line-height: 1.35em;"><a href="/wiki/Public_company" title="Public company">Public</a></td></tr><tr><th scope="row" style="padding-right: 0.5em;"><a href="/wiki/Ticker_symbol" title="Ticker symbol">Traded as</a></th><td style="line-height: 1.35em;"><div class="plainlist"><ul><li><a href="/wiki/NASDAQ" class="mw-redirect" title="NASDAQ">NASDAQ</a>: <a rel="nofollow" class="external text" href="https://www.nasdaq.com/symbol/gild">GILD</a></li><li><a href="/wiki/NASDAQ_Biotechnology_Index" title="NASDAQ Biotechnology Index">NASDAQ Biotechnology Component</a></li><li><a href="/wiki/NASDAQ-100" title="NASDAQ-100">NASDAQ-100 Component</a></li><li><a href="/wiki/S%26P_100" title="S&amp;P 100">S&amp;P 100 Component</a></li><li><a href="/wiki/S%26P_500" class="mw-redirect" title="S&amp;P 500">S&amp;P 500 Component</a></li></ul></div></td></tr><tr><th scope="row" style="padding-right: 0.5em;"><a href="/wiki/International_Securities_Identification_Number" title="International Securities Identification Number">ISIN</a></th><td style="line-height: 1.35em;"><span class="plainlinks nourlexpansion"><a class="external text" href="https://tools.wmflabs.org/isin/?language=en&amp;isin=US3755581036">US3755581036 </a><a href="https://www.wikidata.org/wiki/Q663596?uselang=en#P946" title="Edit this on Wikidata"><img alt="Edit this on Wikidata" src="//upload.wikimedia.org/wikipedia/en/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/10px-OOjs_UI_icon_edit-ltr-progressive.svg.png" decoding="async" width="10" height="10" style="vertical-align: text-top" srcset="//upload.wikimedia.org/wikipedia/en/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/15px-OOjs_UI_icon_edit-ltr-progressive.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/20px-OOjs_UI_icon_edit-ltr-progressive.svg.png 2x" data-file-width="20" data-file-height="20"></a></span></td></tr><tr><th scope="row" style="padding-right: 0.5em;">Industry</th><td class="category" style="line-height: 1.35em;"><a href="/wiki/Pharmaceutics" title="Pharmaceutics">Pharmaceutics</a><br><a href="/wiki/Biotechnology" title="Biotechnology">Biotechnology</a></td></tr><tr><th scope="row" style="padding-right: 0.5em;">Founded</th><td style="line-height: 1.35em;">1987<span class="noprint">; 33 years ago</span><span style="display:none"> (<span class="bday dtstart published updated">1987</span>)</span></td></tr><tr><th scope="row" style="padding-right: 0.5em;">Founder</th><td class="agent" style="line-height: 1.35em;">Michael L. Riordan</td></tr><tr><th scope="row" style="padding-right: 0.5em;">Headquarters</th><td class="label" style="line-height: 1.35em;"><a href="/wiki/Foster_City,_California" title="Foster City, California">Foster City, California</a>, United States</td></tr><tr><th scope="row" style="padding-right: 0.5em;"><div style="padding:0.1em 0;line-height:1.2em;">Area served</div></th><td style="line-height: 1.35em;">Worldwide</td></tr><tr><th scope="row" style="padding-right: 0.5em;"><div style="padding:0.1em 0;line-height:1.2em;">Key people</div></th><td class="agent" style="line-height: 1.35em;"><div class="plainlist"><ul><li>Daniel O’Day<br><span style="font-size:85%;">(<a href="/wiki/CEO" class="mw-redirect" title="CEO">CEO</a> and <a href="/wiki/Chairman#Public_corporations" class="mw-redirect" title="Chairman">Chairman</a>)</span><sup id="cite_ref-8-K20181210_1-0" class="reference"><a href="#cite_note-8-K20181210-1">[1]</a></sup></li><li>Robin L. Washington<br><span style="font-size:85%;">(<a href="/wiki/CFO" class="mw-redirect" title="CFO">CFO</a>)</span><sup id="cite_ref-10-K_2-0" class="reference"><a href="#cite_note-10-K-2">[2]</a></sup></li></ul></div></td></tr><tr><th scope="row" style="padding-right: 0.5em;">Products</th><td style="line-height: 1.35em;"><div class="hlist">
<ul><li><a href="/wiki/Efavirenz/emtricitabine/tenofovir" title="Efavirenz/emtricitabine/tenofovir">Atripla</a></li>
<li><a href="/wiki/Emtricitabine/rilpivirine/tenofovir" title="Emtricitabine/rilpivirine/tenofovir">Complera</a></li>
<li><a href="/wiki/Tenofovir_alafenamide" title="Tenofovir alafenamide">Descovy</a></li>
<li><a href="/wiki/Emtricitabine" title="Emtricitabine">Emtriva</a></li>
<li><a href="/wiki/Elvitegravir/cobicistat/emtricitabine/tenofovir" title="Elvitegravir/cobicistat/emtricitabine/tenofovir">Stribild</a></li>
<li><a href="/wiki/Oseltamivir" title="Oseltamivir">Tamiflu</a></li>
<li><a href="/wiki/Ranolazine" title="Ranolazine">Ranexa</a></li>
<li><a href="/wiki/Ledipasvir/sofosbuvir" title="Ledipasvir/sofosbuvir">Harvoni</a></li>
<li><a href="/wiki/Tenofovir_disoproxil" title="Tenofovir disoproxil">Viread</a></li>
<li><a href="/wiki/Emtricitabine/tenofovir" title="Emtricitabine/tenofovir">Truvada</a></li>
<li><a href="/wiki/Adefovir" title="Adefovir">Hepsera</a></li>
<li><a href="/wiki/Sofosbuvir" title="Sofosbuvir">Sovaldi</a></li>
<li><a href="/wiki/Cobicistat" title="Cobicistat">Tybost</a></li>
<li><a href="/wiki/Elvitegravir" title="Elvitegravir">Vitekta</a></li>
<li><a href="/wiki/Biktarvy" class="mw-redirect" title="Biktarvy">Biktarvy</a></li></ul></div></td></tr><tr><th scope="row" style="padding-right: 0.5em;">Revenue</th><td style="line-height: 1.35em;"><img alt="Decrease" src="//upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/11px-Decrease2.svg.png" decoding="async" title="Decrease" width="11" height="11" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/17px-Decrease2.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/22px-Decrease2.svg.png 2x" data-file-width="300" data-file-height="300"> <span style="white-space: nowrap"><a href="/wiki/United_States_dollar" title="United States dollar">US$</a>22.127 billion</span> <span style="font-size:85%;">(2018)</span><sup id="cite_ref-10-K_2-1" class="reference"><a href="#cite_note-10-K-2">[2]</a></sup></td></tr><tr><th scope="row" style="padding-right: 0.5em;"><div style="padding:0.1em 0;line-height:1.2em;"><a href="/wiki/Earnings_before_interest_and_taxes" title="Earnings before interest and taxes">Operating income</a></div></th><td style="line-height: 1.35em;"><img alt="Decrease" src="//upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/11px-Decrease2.svg.png" decoding="async" title="Decrease" width="11" height="11" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/17px-Decrease2.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/22px-Decrease2.svg.png 2x" data-file-width="300" data-file-height="300"> <span style="white-space: nowrap">US$8.2 billion</span> <span style="font-size:85%;">(2018)</span><sup id="cite_ref-10-K_2-2" class="reference"><a href="#cite_note-10-K-2">[2]</a></sup></td></tr><tr><th scope="row" style="padding-right: 0.5em;"><div style="padding:0.1em 0;line-height:1.2em;"><a href="/wiki/Net_income" title="Net income">Net income</a></div></th><td style="line-height: 1.35em;"><img alt="Increase" src="//upload.wikimedia.org/wikipedia/commons/thumb/b/b0/Increase2.svg/11px-Increase2.svg.png" decoding="async" title="Increase" width="11" height="11" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/b/b0/Increase2.svg/17px-Increase2.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/b/b0/Increase2.svg/22px-Increase2.svg.png 2x" data-file-width="300" data-file-height="300"> <span style="white-space: nowrap">US$5.455 billion</span> <span style="font-size:85%;">(2018)</span><sup id="cite_ref-10-K_2-3" class="reference"><a href="#cite_note-10-K-2">[2]</a></sup></td></tr><tr><th scope="row" style="padding-right: 0.5em;"><span class="nowrap"><a href="/wiki/Asset" title="Asset">Total assets</a></span></th><td style="line-height: 1.35em;"><img alt="Decrease" src="//upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/11px-Decrease2.svg.png" decoding="async" title="Decrease" width="11" height="11" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/17px-Decrease2.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/22px-Decrease2.svg.png 2x" data-file-width="300" data-file-height="300"> <span style="white-space: nowrap">US$63.675 billion</span> <span style="font-size:85%;">(2018)</span><sup id="cite_ref-10-K_2-4" class="reference"><a href="#cite_note-10-K-2">[2]</a></sup></td></tr><tr><th scope="row" style="padding-right: 0.5em;"><span class="nowrap"><a href="/wiki/Equity_(finance)" title="Equity (finance)">Total equity</a></span></th><td style="line-height: 1.35em;"><img alt="Increase" src="//upload.wikimedia.org/wikipedia/commons/thumb/b/b0/Increase2.svg/11px-Increase2.svg.png" decoding="async" title="Increase" width="11" height="11" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/b/b0/Increase2.svg/17px-Increase2.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/b/b0/Increase2.svg/22px-Increase2.svg.png 2x" data-file-width="300" data-file-height="300"> <span style="white-space: nowrap">US$21.534 billion</span> <span style="font-size:85%;">(2018)</span><sup id="cite_ref-10-K_2-5" class="reference"><a href="#cite_note-10-K-2">[2]</a></sup></td></tr><tr><th scope="row" style="padding-right: 0.5em;"><div style="padding:0.1em 0;line-height:1.2em;">Number of employees</div></th><td style="line-height: 1.35em;">11,000 <span style="font-size:85%;">(January 2019)</span><sup id="cite_ref-3" class="reference"><a href="#cite_note-3">[3]</a></sup></td></tr><tr><th scope="row" style="padding-right: 0.5em;">Website</th><td style="line-height: 1.35em;"><span class="url"><a rel="nofollow" class="external text" href="https://www.gilead.com/">www<wbr></wbr>.gilead<wbr></wbr>.com/</a></span> <span class="penicon"><a href="https://www.wikidata.org/wiki/Q663596?uselang=en#P856" title="Edit this on Wikidata"><img alt="Edit this on Wikidata" src="//upload.wikimedia.org/wikipedia/en/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/10px-OOjs_UI_icon_edit-ltr-progressive.svg.png" decoding="async" width="10" height="10" style="vertical-align: text-top" srcset="//upload.wikimedia.org/wikipedia/en/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/15px-OOjs_UI_icon_edit-ltr-progressive.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/20px-OOjs_UI_icon_edit-ltr-progressive.svg.png 2x" data-file-width="20" data-file-height="20"></a></span></td></tr></tbody></table><p>Headquartered and founded in <a href="/wiki/Foster_City,_California" title="Foster City, California">Foster City, California</a>, Gilead is a member of the <a href="/wiki/NASDAQ_Biotechnology_Index" title="NASDAQ Biotechnology Index">NASDAQ Biotechnology Index</a> and the <a href="/wiki/S%26P_500" class="mw-redirect" title="S&amp;P 500">S&amp;P 500</a>.
</p>
<div id="toc" class="toc" role="navigation" aria-labelledby="mw-toc-heading"><input type="checkbox" role="button" id="toctogglecheckbox" class="toctogglecheckbox" style="display:none"><div class="toctitle" lang="en" dir="ltr"><h2 id="mw-toc-heading">Contents</h2><span class="toctogglespan"><label class="toctogglelabel" for="toctogglecheckbox"></label></span></div>
<ul><li class="toclevel-1 tocsection-1"><a href="#History"><span class="tocnumber">1</span> <span class="toctext">History</span></a>
<ul><li class="toclevel-2 tocsection-2"><a href="#Foundation"><span class="tocnumber">1.1</span> <span class="toctext">Foundation</span></a></li>
<li class="toclevel-2 tocsection-3"><a href="#1990-1999:_IPO"><span class="tocnumber">1.2</span> <span class="toctext">1990-1999: IPO</span></a></li>
<li class="toclevel-2 tocsection-4"><a href="#2000_to_2009"><span class="tocnumber">1.3</span> <span class="toctext">2000 to 2009</span></a></li>
<li class="toclevel-2 tocsection-5"><a href="#2010_to_2019"><span class="tocnumber">1.4</span> <span class="toctext">2010 to 2019</span></a>
<ul><li class="toclevel-3 tocsection-6"><a href="#Sovaldi_and_Harvoni"><span class="tocnumber">1.4.1</span> <span class="toctext">Sovaldi and Harvoni</span></a></li>
<li class="toclevel-3 tocsection-7"><a href="#Finances"><span class="tocnumber">1.4.2</span> <span class="toctext">Finances</span></a></li>
<li class="toclevel-3 tocsection-8"><a href="#Prospects_for_the_future"><span class="tocnumber">1.4.3</span> <span class="toctext">Prospects for the future</span></a></li>
<li class="toclevel-3 tocsection-9"><a href="#Tax_structures"><span class="tocnumber">1.4.4</span> <span class="toctext">Tax structures</span></a></li>
</ul></li>
<li class="toclevel-2 tocsection-10"><a href="#Acquisition_history"><span class="tocnumber">1.5</span> <span class="toctext">Acquisition history</span></a></li>
</ul></li>
<li class="toclevel-1 tocsection-11"><a href="#Criticism"><span class="tocnumber">2</span> <span class="toctext">Criticism</span></a></li>
<li class="toclevel-1 tocsection-12"><a href="#References"><span class="tocnumber">3</span> <span class="toctext">References</span></a></li>
<li class="toclevel-1 tocsection-13"><a href="#External_links"><span class="tocnumber">4</span> <span class="toctext">External links</span></a></li>
</ul></div>

</section><h2 class="section-heading" onclick="javascript:mfTempOpenSection(1)"><div class="mw-ui-icon mw-ui-icon-element indicator mw-ui-icon-small mw-ui-icon-flush-left"></div><span class="mw-headline" id="History">History</span><span class="mw-editsection"><a href="/w/index.php?title=Gilead_Sciences&amp;action=edit&amp;section=1" title="Edit section: History" data-section="1" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h2><section class="mf-section-1 collapsible-block" id="mf-section-1">
<h3 class="in-block"><span class="mw-headline" id="Foundation">Foundation</span><span class="mw-editsection"><a href="/w/index.php?title=Gilead_Sciences&amp;action=edit&amp;section=2" title="Edit section: Foundation" data-section="2" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h3>
<table class="infobox" style="width:22em;width: 210px; float: right; clear: right; margin:0 0 1.5em 1.5em"><caption>External video</caption><tbody><tr><td colspan="2" style="text-align:center"><a href="/wiki/File:Gregg_Alton_crop_2012_CHF_HIV_AIDS_058.jpg" class="image"><noscript><img alt="Gregg Alton crop 2012 CHF HIV AIDS 058.jpg" src="//upload.wikimedia.org/wikipedia/commons/thumb/9/9a/Gregg_Alton_crop_2012_CHF_HIV_AIDS_058.jpg/210px-Gregg_Alton_crop_2012_CHF_HIV_AIDS_058.jpg" decoding="async" width="210" height="250" data-file-width="1419" data-file-height="1692"></noscript><span class="lazy-image-placeholder" style="width: 210px;height: 250px;" data-src="//upload.wikimedia.org/wikipedia/commons/thumb/9/9a/Gregg_Alton_crop_2012_CHF_HIV_AIDS_058.jpg/210px-Gregg_Alton_crop_2012_CHF_HIV_AIDS_058.jpg" data-alt="Gregg Alton crop 2012 CHF HIV AIDS 058.jpg" data-width="210" data-height="250"> </span></a></td></tr><tr><td colspan="2" style="text-align:center;text-align: left"><noscript><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/1/1b/Nuvola_apps_kaboodle.svg/16px-Nuvola_apps_kaboodle.svg.png" decoding="async" width="16" height="16" data-file-width="128" data-file-height="128"></noscript><span class="lazy-image-placeholder" style="width: 16px;height: 16px;" data-src="//upload.wikimedia.org/wikipedia/commons/thumb/1/1b/Nuvola_apps_kaboodle.svg/16px-Nuvola_apps_kaboodle.svg.png" data-alt="" data-width="16" data-height="16" data-srcset="//upload.wikimedia.org/wikipedia/commons/thumb/1/1b/Nuvola_apps_kaboodle.svg/24px-Nuvola_apps_kaboodle.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/1/1b/Nuvola_apps_kaboodle.svg/32px-Nuvola_apps_kaboodle.svg.png 2x"> </span> Gregg Alton of Gilead Sciences &amp; others, <a rel="nofollow" class="external text" href="https://vimeo.com/59281508">"The Evolution of HIV/AIDS Therapies: A Conversation"</a>, 2012, <a href="/wiki/Chemical_Heritage_Foundation" class="mw-redirect" title="Chemical Heritage Foundation">Chemical Heritage Foundation</a> via Vimeo</td></tr></tbody></table><p>In June 1987, Gilead Sciences was originally founded under the name <b>Oligogen</b><sup id="cite_ref-Tansey_4-0" class="reference"><a href="#cite_note-Tansey-4">[4]</a></sup> by Michael L. Riordan, a medical doctor.<sup id="cite_ref-boslaugh_5-0" class="reference"><a href="#cite_note-boslaugh-5">[5]</a></sup> Riordan graduated from Washington University in St. Louis, the <a href="/wiki/Johns_Hopkins_School_of_Medicine" title="Johns Hopkins School of Medicine">Johns Hopkins School of Medicine</a> and the <a href="/wiki/Harvard_Business_School" title="Harvard Business School">Harvard Business School</a>.<sup id="cite_ref-6" class="reference"><a href="#cite_note-6">[6]</a></sup> Three scientific advisers worked with Riordan to create the company: <a href="/wiki/Peter_Dervan" title="Peter Dervan">Peter Dervan</a> of <a href="/wiki/California_Institute_of_Technology" title="California Institute of Technology">Caltech</a>, <a href="/wiki/Douglas_A._Melton" title="Douglas A. Melton">Doug Melton</a> of <a href="/wiki/Harvard_University" title="Harvard University">Harvard</a>, and <a href="/wiki/Harold_M._Weintraub" title="Harold M. Weintraub">Harold M. Weintraub</a> of the <a href="/wiki/Fred_Hutchinson_Cancer_Research_Center" title="Fred Hutchinson Cancer Research Center">Fred Hutchinson Cancer Research Center</a>. Riordan served as CEO from the company's founding until 1996.<sup id="cite_ref-7" class="reference"><a href="#cite_note-7">[7]</a></sup><sup id="cite_ref-8" class="reference"><a href="#cite_note-8">[8]</a></sup> <a href="/wiki/Menlo_Ventures" title="Menlo Ventures">Menlo Ventures</a>, a venture capital firm where Riordan had previously worked, made the first investment in Gilead of $2 million.<sup id="cite_ref-auto_9-0" class="reference"><a href="#cite_note-auto-9">[9]</a></sup> Riordan also recruited scientific advisers including <a href="/wiki/Harold_E._Varmus" title="Harold E. Varmus">Harold Varmus</a>, a Nobel laureate who later became Director of the <a href="/wiki/National_Institutes_of_Health" title="National Institutes of Health">National Institutes of Health</a>, and <a href="/wiki/Jack_W._Szostak" title="Jack W. Szostak">Jack Szostak</a>, recipient of the Nobel Prize for Physiology or Medicine in 2009.<sup id="cite_ref-10" class="reference"><a href="#cite_note-10">[10]</a></sup><sup id="cite_ref-11" class="reference"><a href="#cite_note-11">[11]</a></sup></p><p>The company's primary therapeutic focus was in antiviral medicines, a field that interested Riordan after he contracted <a href="/wiki/Dengue_fever" title="Dengue fever">dengue fever</a>.<sup id="cite_ref-12" class="reference"><a href="#cite_note-12">[12]</a></sup> Riordan recruited <a href="/wiki/Donald_Rumsfeld" title="Donald Rumsfeld">Donald Rumsfeld</a> to join the board of directors in 1988,<sup id="cite_ref-Jacobs_13-0" class="reference"><a href="#cite_note-Jacobs-13">[13]</a></sup> followed by <a href="/wiki/Benno_C._Schmidt,_Sr." class="mw-redirect" title="Benno C. Schmidt, Sr.">Benno C. Schmidt, Sr.</a>,<sup class="noprint Inline-Template Template-Fact" style="white-space:nowrap;">[<i><a href="/wiki/Wikipedia:Citation_needed" title="Wikipedia:Citation needed"><span title="This claim needs references to reliable sources. (April 2020)">citation needed</span></a></i>]</sup> <a href="/wiki/Gordon_Moore" title="Gordon Moore">Gordon Moore</a>,<sup id="cite_ref-Jacobs_13-1" class="reference"><a href="#cite_note-Jacobs-13">[13]</a></sup> and <a href="/wiki/George_P._Shultz" class="mw-redirect" title="George P. Shultz">George P. Shultz</a>.<sup id="cite_ref-Jacobs_13-2" class="reference"><a href="#cite_note-Jacobs-13">[13]</a></sup> Riordan tried to recruit <a href="/wiki/Warren_Buffett" title="Warren Buffett">Warren Buffett</a> as an investor and board member, but was unsuccessful.<sup id="cite_ref-boslaugh_5-1" class="reference"><a href="#cite_note-boslaugh-5">[5]</a></sup></p><p>The company focused its early research on making small strands of DNA (<a href="/wiki/Oligomer" title="Oligomer">oligomers</a>, or more particularly, <a href="/wiki/Oligonucleotide" title="Oligonucleotide">oligonucleotides</a>) to target specific genetic code sequences — that is, <a href="/wiki/Antisense_therapy" title="Antisense therapy">antisense therapy</a>, a form of <a href="/wiki/Gene_therapy" title="Gene therapy">gene therapy</a>.<sup id="cite_ref-Tansey_4-1" class="reference"><a href="#cite_note-Tansey-4">[4]</a></sup> Because of the expected healing potential of such research, Oligogen soon changed its name to Gilead Sciences, after the reputed healing properties of the ancient <a href="/wiki/Balm_of_Gilead" title="Balm of Gilead">Balm of Gilead</a>.<sup id="cite_ref-Tansey_4-2" class="reference"><a href="#cite_note-Tansey-4">[4]</a></sup> By 1988, the company had moved its headquarters to Foster City's Vintage Park neighborhood, where it has been based ever since.<sup id="cite_ref-Tansey_4-3" class="reference"><a href="#cite_note-Tansey-4">[4]</a></sup> The company began to develop small molecule antiviral therapeutics in 1991, when the company in-licensed a group of nucleotide compounds including <a href="/wiki/Tenofovir" class="mw-redirect" title="Tenofovir">tenofovir</a>.<sup id="cite_ref-boslaugh_5-2" class="reference"><a href="#cite_note-boslaugh-5">[5]</a></sup></p>
<h3 class="in-block"><span class="mw-headline" id="1990-1999:_IPO">1990-1999: IPO</span><span class="mw-editsection"><a href="/w/index.php?title=Gilead_Sciences&amp;action=edit&amp;section=3" title="Edit section: 1990-1999: IPO" data-section="3" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h3>
<p>Gilead's antisense intellectual property portfolio was sold to <a href="/wiki/Ionis_Pharmaceuticals" title="Ionis Pharmaceuticals">Ionis Pharmaceuticals</a>. Gilead debuted on the <a href="/wiki/NASDAQ" class="mw-redirect" title="NASDAQ">NASDAQ</a> in January 1992. Its <a href="/wiki/Initial_public_offering" title="Initial public offering">initial public offering</a> raised $86.25 million in proceeds.<sup class="noprint Inline-Template Template-Fact" style="white-space:nowrap;">[<i><a href="/wiki/Wikipedia:Citation_needed" title="Wikipedia:Citation needed"><span title="This claim needs references to reliable sources. (April 2020)">citation needed</span></a></i>]</sup></p><p>In June 1996, Gilead launched Vistide (<a href="/wiki/Cidofovir" title="Cidofovir">cidofovir</a> injection) for the treatment of <a href="/wiki/Cytomegalovirus" title="Cytomegalovirus">cytomegalovirus</a> (CMV) <a href="/wiki/Retinitis" title="Retinitis">retinitis</a> in patients with <a href="/wiki/AIDS" class="mw-redirect" title="AIDS">AIDS</a>.<sup class="noprint Inline-Template Template-Fact" style="white-space:nowrap;">[<i><a href="/wiki/Wikipedia:Citation_needed" title="Wikipedia:Citation needed"><span title="This claim needs references to reliable sources. (April 2020)">citation needed</span></a></i>]</sup></p><p>In January 1997, <a href="/wiki/Donald_Rumsfeld" title="Donald Rumsfeld">Donald Rumsfeld</a> was appointed Chairman, but left the board in January 2001 when he was appointed <a href="/wiki/United_States_Secretary_of_Defense" title="United States Secretary of Defense">United States Secretary of Defense</a> during <a href="/wiki/George_W._Bush" title="George W. Bush">George W. Bush</a>'s first term as President.<sup id="cite_ref-14" class="reference"><a href="#cite_note-14">[14]</a></sup></p><p>In March 1999, Gilead acquired NeXstar Pharmaceuticals of <a href="/wiki/Boulder,_Colorado" title="Boulder, Colorado">Boulder, Colorado</a>. At the time, NeXstar's annual sales of $130 million was three times Gilead's sales; it sold AmBisome, an injectable fungal treatment, and DaunoXome, an <a href="/wiki/Oncology" title="Oncology">oncology</a> drug taken by <a href="/wiki/HIV" title="HIV">HIV</a> patients. That same year, <a href="/wiki/Hoffmann-La_Roche" title="Hoffmann-La Roche">Roche</a> announced FDA approval of <a href="/wiki/Tamiflu" class="mw-redirect" title="Tamiflu">Tamiflu</a> (<a href="/wiki/Oseltamivir" title="Oseltamivir">oseltamivir</a>) for the treatment of <a href="/wiki/Influenza" title="Influenza">influenza</a>.<sup id="cite_ref-15" class="reference"><a href="#cite_note-15">[15]</a></sup> Tamiflu was originally discovered by Gilead and licensed to Roche for late-phase development and marketing.<sup class="noprint Inline-Template Template-Fact" style="white-space:nowrap;">[<i><a href="/wiki/Wikipedia:Citation_needed" title="Wikipedia:Citation needed"><span title="This claim needs references to reliable sources. (April 2020)">citation needed</span></a></i>]</sup></p><p>One reason for entering into the Tamiflu licensing agreement was that with only 350 employees, Gilead still did not yet have the capability to sell its drugs directly to overseas buyers.<sup id="cite_ref-Abate_16-0" class="reference"><a href="#cite_note-Abate-16">[16]</a></sup>  To avoid having to license future drugs in order to access international markets, Gilead simply acquired the 480-employee NeXstar, which had already built its own sales force in Europe to market AmBisome there.<sup id="cite_ref-Abate_16-1" class="reference"><a href="#cite_note-Abate-16">[16]</a></sup></p>
<h3 class="in-block"><span class="mw-headline" id="2000_to_2009">2000 to 2009</span><span class="mw-editsection"><a href="/w/index.php?title=Gilead_Sciences&amp;action=edit&amp;section=4" title="Edit section: 2000 to 2009" data-section="4" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h3>
<p>Viread (<a href="/wiki/Tenofovir" class="mw-redirect" title="Tenofovir">tenofovir</a>) achieved first approval in 2001 for the treatment of HIV.<sup id="cite_ref-17" class="reference"><a href="#cite_note-17">[17]</a></sup></p><p>In 2002 Gilead changed its corporate strategy to focus exclusively on antivirals, and sold its cancer assets to <a href="/wiki/OSI_Pharmaceuticals" title="OSI Pharmaceuticals">OSI Pharmaceuticals</a> for $200 million.<sup id="cite_ref-LAT2002_18-0" class="reference"><a href="#cite_note-LAT2002-18">[18]</a></sup></p><p>In December 2002, Gilead and Triangle Pharmaceuticals announced that Gilead would acquire Triangle for around $464 million; Triangle's lead drug was <a href="/wiki/Emtricitabine" title="Emtricitabine">emtricitabine</a> that was near FDA approval, and it had two other antivirals in its pipeline.<sup id="cite_ref-LAT2002_18-1" class="reference"><a href="#cite_note-LAT2002-18">[18]</a></sup><sup id="cite_ref-19" class="reference"><a href="#cite_note-19">[19]</a></sup> The company also announced its first full year of profitability. Later that year Hepsera (<a href="/wiki/Adefovir" title="Adefovir">adefovir</a>) was approved for the treatment of chronic <a href="/wiki/Hepatitis_B" title="Hepatitis B">hepatitis B</a>, and Emtriva (<a href="/wiki/Emtricitabine" title="Emtricitabine">emtricitabine</a>) for the treatment of HIV.
</p><p>During this era, Gilead completed its gradual evolution from a biotech startup into a pharmaceutical company.<sup id="cite_ref-Tansey_4-4" class="reference"><a href="#cite_note-Tansey-4">[4]</a></sup><sup id="cite_ref-Jacobs_13-3" class="reference"><a href="#cite_note-Jacobs-13">[13]</a></sup>  The <i>San Francisco Chronicle</i> noted that by 2003, the Gilead corporate campus in Foster City had expanded to "seven low-slung sand-colored buildings around a tiny lake on which ducks happily paddle."<sup id="cite_ref-Tansey_4-5" class="reference"><a href="#cite_note-Tansey-4">[4]</a></sup>  Like many startups, Gilead originally leased its space, but in 2004, the company paid $123 million to buy all its headquarters buildings from its landlords.<sup id="cite_ref-Jacobs_13-4" class="reference"><a href="#cite_note-Jacobs-13">[13]</a></sup>  However, even as Gilead developed its ability to distribute and sell its own drugs, it remained distinct from most pharmaceutical companies in terms of its strong reliance on subcontracting most of its manufacturing to <a href="/wiki/Contract_manufacturing_organization" title="Contract manufacturing organization">contract manufacturing organizations</a>.<sup id="cite_ref-Stanton_20-0" class="reference"><a href="#cite_note-Stanton-20">[20]</a></sup></p><p>In 2004, Gilead launched Truvada. Years later, through efforts of activists and other groups, Gilead was convinced that a fixed-dose combination of <a href="/wiki/Tenofovir" class="mw-redirect" title="Tenofovir">tenofovir</a> and <a href="/wiki/Emtricitabine" title="Emtricitabine">emtricitabine</a> could be used as a pre-exposure prophylactic against the transmission of HIV.<sup id="cite_ref-21" class="reference"><a href="#cite_note-21">[21]</a></sup></p><p>In 2006, Gilead completed two acquisitions that allowed the company to branch out from its historical antiviral franchise into the <a href="/wiki/Cardiovascular" class="mw-redirect" title="Cardiovascular">cardiovascular</a> and <a href="/wiki/Respiratory" class="mw-redirect" title="Respiratory">respiratory</a> therapeutic arenas. Under an agreement with <a href="/wiki/GlaxoSmithKline" title="GlaxoSmithKline">GlaxoSmithKline</a>, Myogen marketed <a href="/wiki/Flolan" class="mw-redirect" title="Flolan">Flolan</a> (<a href="/wiki/Epoprostenol_sodium" class="mw-redirect" title="Epoprostenol sodium">epoprostenol sodium</a>) in the United States for the treatment of <a href="/wiki/Primary_pulmonary_hypertension" class="mw-redirect" title="Primary pulmonary hypertension">primary pulmonary hypertension</a>. Additionally, Myogen was developing (in Phase 3 studies) darusentan,<sup id="cite_ref-22" class="reference"><a href="#cite_note-22">[22]</a></sup> also an endothelin receptor antagonist, for the potential treatment of resistant <a href="/wiki/Hypertension" title="Hypertension">hypertension</a>.
</p><p>In 2006, the company acquired Corus Pharma, Inc. for $365 million. The acquisition of Corus signaled Gilead's entry into the respiratory arena. Corus was developing aztreonam lysine for the treatment of patients with <a href="/wiki/Cystic_fibrosis" title="Cystic fibrosis">cystic fibrosis</a> who are infected with <i><a href="/wiki/Pseudomonas_aeruginosa" title="Pseudomonas aeruginosa">Pseudomonas aeruginosa</a></i>. 
</p><p>In July 2006, the U.S. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA) approved <a href="/wiki/Atripla" class="mw-redirect" title="Atripla">Atripla</a>, a once a day single tablet regimen for HIV, combining Sustiva (<a href="/wiki/Efavirenz" title="Efavirenz">efavirenz</a>), a <a href="/wiki/Bristol-Myers_Squibb" title="Bristol-Myers Squibb">Bristol-Myers Squibb</a> product, and Truvada (<a href="/wiki/Emtricitabine" title="Emtricitabine">emtricitabine</a> and <a href="/wiki/Tenofovir_disoproxil" title="Tenofovir disoproxil">tenofovir disoproxil</a>), a Gilead product.<sup id="cite_ref-23" class="reference"><a href="#cite_note-23">[23]</a></sup><sup id="cite_ref-24" class="reference"><a href="#cite_note-24">[24]</a></sup></p><p>Gilead purchased Raylo Chemicals, Inc. in November 2006 for a price of $133.3 million.<sup id="cite_ref-25" class="reference"><a href="#cite_note-25">[25]</a></sup> Raylo Chemical, based in <a href="/wiki/Edmonton,_Alberta" class="mw-redirect" title="Edmonton, Alberta">Edmonton, Alberta</a>, was a wholly owned subsidiary of <a href="/wiki/Degussa_AG" class="mw-redirect" title="Degussa AG">Degussa AG</a>, a German company.  Raylo Chemical was a custom manufacturer of active pharmaceutical ingredients and advanced intermediates for the pharmaceutical and biopharmaceutical industries. Later in the same year Gilead acquired Myogen, Inc. for $2.5 billion (then its largest acquisition). With two drugs in development (ambrisentan and darusentan), and one marketed product (Flolan) for pulmonary diseases, the acquisition of Myogen has solidified Gilead's position in this therapeutic arena.
</p><p>Gilead expanded its move into respiratory therapeutics in 2007 by entering into a licensing agreement with Parion for an <a href="/wiki/Epithelial_sodium_channel" title="Epithelial sodium channel">epithelial sodium channel</a> inhibitor for the treatment of pulmonary diseases, including cystic fibrosis, <a href="/wiki/Chronic_obstructive_pulmonary_disease" title="Chronic obstructive pulmonary disease">chronic obstructive pulmonary disease</a> and <a href="/wiki/Bronchiectasis" title="Bronchiectasis">bronchiectasis</a>.<sup id="cite_ref-26" class="reference"><a href="#cite_note-26">[26]</a></sup></p><p>In 2009, the company  acquired CV Therapeutics, Inc. for $1.4 billion, bringing Ranexa and Lexiscan into Gilead.<sup id="cite_ref-:0_27-0" class="reference"><a href="#cite_note-:0-27">[27]</a></sup> Ranexa is a cardiovascular drug used to treat chest pain related to coronary artery disease, with both of these products and pipeline building out Gilead's cardiovascular franchise.<sup id="cite_ref-:0_27-1" class="reference"><a href="#cite_note-:0-27">[27]</a></sup> Later that year, the company was named one of the Fastest Growing Companies by <i><a href="/wiki/Fortune_(magazine)" title="Fortune (magazine)">Fortune</a></i>.<sup id="cite_ref-28" class="reference"><a href="#cite_note-28">[28]</a></sup><sup id="cite_ref-29" class="reference"><a href="#cite_note-29">[29]</a></sup> In the same year, they were also named as one America's Top Companies to work for by <i><a href="/wiki/Forbes" title="Forbes">Forbes</a></i>.<sup class="noprint Inline-Template Template-Fact" style="white-space:nowrap;">[<i><a href="/wiki/Wikipedia:Citation_needed" title="Wikipedia:Citation needed"><span title="This claim needs references to reliable sources. (April 2020)">citation needed</span></a></i>]</sup></p>
<h3 class="in-block"><span class="mw-headline" id="2010_to_2019">2010 to 2019</span><span class="mw-editsection"><a href="/w/index.php?title=Gilead_Sciences&amp;action=edit&amp;section=5" title="Edit section: 2010 to 2019" data-section="5" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h3>
<p>In 2010, the company acquired CGI Pharmaceuticals for $120 million, expanding Gilead's research expertise into kinase biology and chemistry. Later that year, the company acquired Arresto Biosciences, Inc. for $225 million, obtaining developmental-stage research for treating fibrotic diseases and cancer.<sup id="cite_ref-30" class="reference"><a href="#cite_note-30">[30]</a></sup></p><p>In February 2011, the company acquired Calistoga Pharmaceuticals for $375 million ($225 million plus milestone payments). The acquisition boosted Gilead's oncology and inflammation areas.<sup id="cite_ref-31" class="reference"><a href="#cite_note-31">[31]</a></sup> Later that year, Gilead made its most important acquisition — and by then most expensive — with the $10.4 billion purchase of <a href="/wiki/Pharmasset" title="Pharmasset">Pharmasset</a>, Inc. This transaction helped cement Gilead as the leader in treatment of the <a href="/wiki/Hepatitis_C_virus" title="Hepatitis C virus">hepatitis C virus</a> by giving it control of <a href="/wiki/Sofosbuvir" title="Sofosbuvir">sofosbuvir</a> (see below). 
</p><p>In October 2011, Gilead broke ground on a massive multi-year expansion of its 17-building headquarters campus in Foster City.<sup id="cite_ref-Leuty_32-0" class="reference"><a href="#cite_note-Leuty-32">[32]</a></sup>  By replacing eight one or two-story buildings with seven new structures ranging as tall as 10 stories, Gilead nearly doubled its headquarters real estate footprint from about 620,000 square feet to about 1.2 million square feet.<sup id="cite_ref-Leuty_32-1" class="reference"><a href="#cite_note-Leuty-32">[32]</a></sup></p><p>On July 16, 2012, the FDA approved Gilead's <a href="/wiki/Truvada" class="mw-redirect" title="Truvada">Truvada</a> for prevention of HIV infection (it was already approved for treating HIV). The pill was a preventive measure (<a href="/wiki/Pre-exposure_prophylaxis#PrEP_for_HIV" title="Pre-exposure prophylaxis">PrEP</a>) for people at high risk of getting HIV through sexual activity.<sup id="cite_ref-33" class="reference"><a href="#cite_note-33">[33]</a></sup></p><p>In 2013, the company acquired YM Biosciences, Inc. for $510 million. The acquisition brings drug candidate <a href="/wiki/CYT387" class="mw-redirect" title="CYT387">CYT387</a>, an orally-administered, once-daily, selective inhibitor of the <a href="/wiki/Janus_kinase" title="Janus kinase">Janus kinase</a> (JAK) family, specifically JAK1 and JAK2, into Gilead's oncology pipeline. The JAK enzymes have been implicated in myeloproliferative diseases, inflammatory disorders, and certain cancers.
</p><p>In 2015, the company made a trio of acquisitions:
</p>
<ul><li>It bought Phenex Pharmaceuticals for $470 million. Its Farnesoid X Receptor (FXR) program used small-molecule FXR agonists in the treatment of liver diseases such as <a href="/wiki/Non-alcoholic_steatohepatitis" class="mw-redirect" title="Non-alcoholic steatohepatitis">non-alcoholic steatohepatitis</a>.<sup id="cite_ref-34" class="reference"><a href="#cite_note-34">[34]</a></sup></li>
<li>It bought EpiTherapeutics for $65 million. This acquisition gave Gilead first-in-class small molecule inhibitors of <a href="/wiki/Demethylase#Histone_demethylation" title="Demethylase">histone demethylases</a> involved in regulating gene transcription in cancer.<sup id="cite_ref-35" class="reference"><a href="#cite_note-35">[35]</a></sup></li>
<li>It paid $425 million for a 15% equity stake in Galapagos NV, with additional payments for Gilead to license the experimental anti-inflammatory drug <a href="/wiki/Filgotinib" title="Filgotinib">filgotinib</a>, which may treat rheumatoid arthritis, <a href="/wiki/Ulcerative_colitis" title="Ulcerative colitis">ulcerative colitis</a>, and <a href="/wiki/Crohn%27s_disease" title="Crohn's disease">Crohn's disease</a>.<sup id="cite_ref-36" class="reference"><a href="#cite_note-36">[36]</a></sup></li></ul><p>In 2016, the company acquired Nimbus Apollo, Inc. for $400 million, giving Gilead control of the compound NDI-010976 (an ACC inhibitor) and other preclinical ACC inhibitors for the treatment of <a href="/wiki/Non-alcoholic_steatohepatitis" class="mw-redirect" title="Non-alcoholic steatohepatitis">non-alcoholic steatohepatitis</a> and for the potential treatment of <a href="/wiki/Hepatocellular_carcinoma" title="Hepatocellular carcinoma">hepatocellular carcinoma</a>.<sup id="cite_ref-37" class="reference"><a href="#cite_note-37">[37]</a></sup><sup id="cite_ref-38" class="reference"><a href="#cite_note-38">[38]</a></sup> Also in 2016, the company was named the most generous company on the 2016 Fortune list of The Most Generous Companies of the <a href="/wiki/Fortune_500" title="Fortune 500">Fortune 500</a>. Charitable donations to HIV/AIDS and liver disease organizations totaled over 440 million in 2015.<sup id="cite_ref-39" class="reference"><a href="#cite_note-39">[39]</a></sup></p><p>In August 2017, the company announced it would acquire <a href="/wiki/Kite_Pharma" title="Kite Pharma">Kite Pharma</a> for $11.9 billion,<sup id="cite_ref-40" class="reference"><a href="#cite_note-40">[40]</a></sup> equating to $180 cash per share, a 29% premium over the closing price of the shares. The deal will add the promising <a href="/wiki/CAR-T" class="mw-redirect" title="CAR-T">CAR-T</a> candidate to the companys existing portfolio.<sup id="cite_ref-41" class="reference"><a href="#cite_note-41">[41]</a></sup> In November, the company announced it will acquire Cell Design Labs for up to $567 million, after it indirectly acquired a stake of 12.2% via the Kite Pharma deal.<sup id="cite_ref-42" class="reference"><a href="#cite_note-42">[42]</a></sup></p><p>On May 9, 2019, the U.S. Department of Health and Human Services announced that Gilead Sciences will donate Truvada, the only drug approved to prevent infection with H.I.V., for free to 200,000 patients annually for 11 years. <sup id="cite_ref-43" class="reference"><a href="#cite_note-43">[43]</a></sup> On December 3, 2019, HHS explained how the government would distribute the donated drugs. The new program called Ready, Set, PrEP is accepting applications from any patient who doesn't have health insurance, has a valid prescription for PrEP and has had a recent negative H.I.V. test. To apply, patients can call 855-477-8410, online at <a rel="nofollow" class="external text" href="https://www.getyourprep.com/">www.getyourprep.com</a> or in person at participating health care provider. HHS Secretary Alex Azar explained that the U.S. government will pay Gilead $200 per bottle for 30 pills for costs associated with getting the drug from factories into the eventual hands of patients.<sup id="cite_ref-44" class="reference"><a href="#cite_note-44">[44]</a></sup></p><p>In March 2020, the company announced it would acquire <a href="/w/index.php?title=Forty_Seven_Inc.&amp;action=edit&amp;redlink=1" class="new" title="Forty Seven Inc. (page does not exist)">Forty Seven Inc.</a> for $95.50 a share ($4.9 billion in total).<sup id="cite_ref-45" class="reference"><a href="#cite_note-45">[45]</a></sup><sup id="cite_ref-46" class="reference"><a href="#cite_note-46">[46]</a></sup><sup id="cite_ref-47" class="reference"><a href="#cite_note-47">[47]</a></sup> On April 7, 2020, Gilead completed acquisition of Forty Seven, Inc. for "$95.50 per share, net to the seller in cash, without interest, or approximately $4.9 billion in the aggregate."<sup id="cite_ref-48" class="reference"><a href="#cite_note-48">[48]</a></sup><sup id="cite_ref-49" class="reference"><a href="#cite_note-49">[49]</a></sup></p>
<h4 class="in-block"><span class="mw-headline" id="Sovaldi_and_Harvoni">Sovaldi and Harvoni</span><span class="mw-editsection"><a href="/w/index.php?title=Gilead_Sciences&amp;action=edit&amp;section=6" title="Edit section: Sovaldi and Harvoni" data-section="6" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h4>
<p>The drug <a href="/wiki/Sofosbuvir" title="Sofosbuvir">sofosbuvir</a> had been part of the 2011 acquisition of Pharmasset. In 2013, the FDA approved this drug, under the trade name Sovaldi, as a treatment for the <a href="/wiki/Hepatitis_C_virus" title="Hepatitis C virus">hepatitis C virus</a>. <i><a href="/wiki/Forbes" title="Forbes">Forbes</a></i> magazine ranked Gilead its number 4 drug company, citing a market capitalization of US$113 billion and stock appreciation of 100%, and describing their 2011 purchase of <a href="/wiki/Pharmasset" title="Pharmasset">Pharmasset</a> for $11 billion as “one of the best pharma acquisitions ever”.<sup id="cite_ref-50" class="reference"><a href="#cite_note-50">[50]</a></sup> <a href="/wiki/Deutsche_Bank" title="Deutsche Bank">Deutsche Bank</a> estimated Sovaldi sales in the year's final quarter would be $53 million,<sup id="cite_ref-51" class="reference"><a href="#cite_note-51">[51]</a></sup> and <i><a href="/wiki/Barron%27s_(newspaper)" title="Barron's (newspaper)">Barron's</a></i> noted the FDA approval and subsequent strong sales of the “potentially revolutionary” drug as a positive indicator for the stock.<sup id="cite_ref-52" class="reference"><a href="#cite_note-52">[52]</a></sup></p><p>On July 11, 2014, the <a href="/wiki/United_States_Senate_Committee_on_Finance" title="United States Senate Committee on Finance">United States Senate Committee on Finance</a> investigated Sovaldi's high price ($1,000 per pill; $84,000 for the full 12-week regimen). Senators questioned the extent to which the market was operating “efficiently and rationally”, and committee chairman <a href="/wiki/Ron_Wyden" title="Ron Wyden">Ron Wyden</a> (<a href="/wiki/U.S._Democratic_Party" class="mw-redirect" title="U.S. Democratic Party">D</a>-<a href="/wiki/Oregon" title="Oregon">Oregon</a>) and ranking minority member <a href="/wiki/Chuck_Grassley" title="Chuck Grassley">Chuck Grassley</a> (<a href="/wiki/U.S._Republican_Party" class="mw-redirect" title="U.S. Republican Party">R</a>-<a href="/wiki/Iowa" title="Iowa">Iowa</a>) wrote to CEO John C. Martin asking Gilead to justify the price for this drug.<sup id="cite_ref-53" class="reference"><a href="#cite_note-53">[53]</a></sup> The committee hearings did not result in new law, but in 2014 and 2015, due to negotiated and mandated discounts, Sovaldi was sold well below the list price.<sup id="cite_ref-Martin_2014_54-0" class="reference"><a href="#cite_note-Martin_2014-54">[54]</a></sup> For poorer countries, Gilead licensed multiple companies to produce generic versions of Sovaldi; in India, a pill's price was as low as $4.29.<sup id="cite_ref-55" class="reference"><a href="#cite_note-55">[55]</a></sup></p><p>Gilead later combined Sovaldi with other antivirals in single-pill combinations. First, Sovaldi was combined with <a href="/wiki/Ledipasvir" title="Ledipasvir">ledipasvir</a> and marketed as <a href="/wiki/Ledipasvir/sofosbuvir" title="Ledipasvir/sofosbuvir">Harvoni</a>. This treatment for hepatitis C cures the patient in 94% to 99% of cases (HCV genotype 1).<sup id="cite_ref-Ke2015_56-0" class="reference"><a href="#cite_note-Ke2015-56">[56]</a></sup> By 2017, Gilead was reporting drastic drops in Sovaldi revenue from year to year, not only because of pricing pressure but because the number of suitable patients decreased.<sup id="cite_ref-57" class="reference"><a href="#cite_note-57">[57]</a></sup> Later single-pill combinations were <a href="/wiki/Epclusa" class="mw-redirect" title="Epclusa">Epclusa</a> (with <a href="/wiki/Velpatasvir" title="Velpatasvir">velpatasvir</a>) and <a href="/wiki/Vosevi" class="mw-redirect" title="Vosevi">Vosevi</a> (with <a href="/wiki/Velpatasvir" title="Velpatasvir">velpatasvir</a> and <a href="/wiki/Voxilaprevir" title="Voxilaprevir">voxilaprevir</a>).
</p>
<h4 class="in-block"><span class="mw-headline" id="Finances">Finances</span><span class="mw-editsection"><a href="/w/index.php?title=Gilead_Sciences&amp;action=edit&amp;section=7" title="Edit section: Finances" data-section="7" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h4>
<p>For the fiscal year 2017, Gilead Sciences Insurance reported earnings of US$4.628 billion, with an annual revenue of US$26.107 billion, a decline of 14.1% over the previous fiscal cycle. Gilead Sciences's shares traded at over $70 per share, and its market capitalization was valued at US$93.4 billion in October 2018.<sup id="cite_ref-58" class="reference"><a href="#cite_note-58">[58]</a></sup></p>
<table class="wikitable float-left" style="text-align: right;"><tbody><tr><th>Year
</th>
<th>Revenue<br>in mil. USD$
</th>
<th>Net income<br>in mil. USD$
</th>
<th>Total assets<br>in mil. USD$
</th>
<th>Price per share<br>in USD$
</th>
<th>Employees
</th></tr><tr><td>2005
</td>
<td>2,028
</td>
<td>814
</td>
<td>3,766
</td>
<td>9.77
</td>
<td>
</td></tr><tr><td>2006
</td>
<td>3,026
</td>
<td>−1,190
</td>
<td>4,086
</td>
<td>14.31
</td>
<td>
</td></tr><tr><td>2007
</td>
<td>4,230
</td>
<td>1,585
</td>
<td>5,835
</td>
<td>18.30
</td>
<td>
</td></tr><tr><td>2008
</td>
<td>5,336
</td>
<td>1,979
</td>
<td>6,937
</td>
<td>22.74
</td>
<td>
</td></tr><tr><td>2009
</td>
<td>7,011
</td>
<td>2,636
</td>
<td>9,699
</td>
<td>21.32
</td>
<td>
</td></tr><tr><td>2010
</td>
<td>7,949
</td>
<td>2,901
</td>
<td>11,593
</td>
<td>18.15
</td>
<td>
</td></tr><tr><td>2011
</td>
<td>8,385
</td>
<td>2,804
</td>
<td>17,303
</td>
<td>18.46
</td>
<td>
</td></tr><tr><td>2012
</td>
<td>9,702
</td>
<td>2,592
</td>
<td>21,240
</td>
<td>26.13
</td>
<td>
</td></tr><tr><td>2013
</td>
<td>11,202
</td>
<td>3,075
</td>
<td>22,579
</td>
<td>51.83
</td>
<td>6,000
</td></tr><tr><td>2014
</td>
<td>24,890
</td>
<td>12,101
</td>
<td>34,664
</td>
<td>82.82
</td>
<td>7,000
</td></tr><tr><td>2015
</td>
<td>32,639
</td>
<td>18,108
</td>
<td>51,716
</td>
<td>98.83
</td>
<td>8,000
</td></tr><tr><td>2016
</td>
<td>30,390
</td>
<td>13,501
</td>
<td>56,977
</td>
<td>78.87
</td>
<td>9,000
</td></tr><tr><td>2017
</td>
<td>26,107
</td>
<td>4,628
</td>
<td>70,283
</td>
<td>70.13
</td>
<td>10,000
</td></tr><tr><td>2018
</td>
<td>22,127
</td>
<td>5,455
</td>
<td>63,675
</td>
<td>63.86
</td>
<td>11,000<sup id="cite_ref-59" class="reference"><a href="#cite_note-59">[59]</a></sup></td></tr></tbody></table><h4 class="in-block"><span class="mw-headline" id="Prospects_for_the_future">Prospects for the future</span><span class="mw-editsection"><a href="/w/index.php?title=Gilead_Sciences&amp;action=edit&amp;section=8" title="Edit section: Prospects for the future" data-section="8" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h4>
<p>As of 2017, Gilead's challenge is to develop or acquire new blockbuster drugs before its current revenue-producers wane or their patent protection expires. Gilead benefited from the expansion of <a href="/wiki/Medicaid" title="Medicaid">Medicaid</a> in the ACA; Leerink analyst Geoffrey Porges wrote that Gilead's HIV drugs could face funding pressure under reform proposals.<sup id="cite_ref-60" class="reference"><a href="#cite_note-60">[60]</a></sup> Gilead has $32 billion in cash, but $27.4 billion is outside the U.S. and is unavailable for acquisitions unless Gilead pays U.S. tax on it, though it could borrow against it.<sup id="cite_ref-61" class="reference"><a href="#cite_note-61">[61]</a></sup> Gilead would benefit from proposals to let companies repatriate offshore capital with minimal further taxation.<sup id="cite_ref-62" class="reference"><a href="#cite_note-62">[62]</a></sup></p><p>Gilead's <a href="/wiki/Entospletinib" title="Entospletinib">Entospletinib</a> has shown a 90% complete <a href="/wiki/Response_rate_(medicine)" title="Response rate (medicine)">response rate</a> for MLL type AML.<sup id="cite_ref-63" class="reference"><a href="#cite_note-63">[63]</a></sup></p>
<h4 class="in-block"><span class="mw-headline" id="Tax_structures">Tax structures</span><span class="mw-editsection"><a href="/w/index.php?title=Gilead_Sciences&amp;action=edit&amp;section=9" title="Edit section: Tax structures" data-section="9" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h4>
<p>On December 26, 2018, <i><a href="/wiki/The_Times" title="The Times">The Times</a></i> reported that Gilead had used the <a href="/wiki/Double_Irish_arrangement" title="Double Irish arrangement">Double Irish arrangement</a> to avoid U.S. corporate taxes on non–U.S. profits, reporting that "A US pharmaceutical firm used a controversial tax loophole arrangement to shift almost €20 billion in profits through an Irish entity in just two years".<sup id="cite_ref-64" class="reference"><a href="#cite_note-64">[64]</a></sup></p>
<h3 class="in-block"><span class="mw-headline" id="Acquisition_history">Acquisition history</span><span class="mw-editsection"><a href="/w/index.php?title=Gilead_Sciences&amp;action=edit&amp;section=10" title="Edit section: Acquisition history" data-section="10" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h3>
<div class="mw-collapsible mw-collapsible-leftside-toggle mw-collapsed" style="box-sizing:border-box;width:100%;font-size:95%;padding:4px;border:none;"><div style="font-size:100%;line-height:1.6;font-weight:bold;background:transparent;text-align:left;;background:white;">Illustration of the company's mergers, acquisitions and historical predecessors</div><div class="mw-collapsible-content" style="background:transparent;text-align:left;;">
<style data-mw-deduplicate="TemplateStyles:r935768785">.mw-parser-output table.clade{border-spacing:0;margin:0;font-size:100%;line-height:100%;border-collapse:separate;width:auto}.mw-parser-output table.clade table.clade{width:100%}.mw-parser-output table.clade td.clade-label{width:0.7em;padding:0 0.15em;vertical-align:bottom;text-align:center;border-left:1px solid;border-bottom:1px solid;white-space:nowrap}.mw-parser-output table.clade td.clade-fixed-width{overflow:hidden;text-overflow:ellipsis}.mw-parser-output table.clade td.clade-fixed-width:hover{overflow:visible}.mw-parser-output table.clade td.clade-label.first{border-left:none;border-right:none}.mw-parser-output table.clade td.clade-label.reverse{border-left:none;border-right:1px solid}.mw-parser-output table.clade td.clade-slabel{padding:0 0.15em;vertical-align:top;text-align:center;border-left:1px solid;white-space:nowrap}.mw-parser-output table.clade td.clade-slabel:hover{overflow:visible}.mw-parser-output table.clade td.clade-slabel.last{border-left:none;border-right:none}.mw-parser-output table.clade td.clade-slabel.reverse{border-left:none;border-right:1px solid}.mw-parser-output table.clade td.clade-bar{vertical-align:middle;text-align:left;padding:0 0.5em;position:relative}.mw-parser-output table.clade td.clade-bar.reverse{text-align:right;position:relative}.mw-parser-output table.clade td.clade-leaf{border:0;padding:0;text-align:left}.mw-parser-output table.clade td.clade-leafR{border:0;padding:0;text-align:right}.mw-parser-output table.clade td.clade-leaf.reverse{text-align:right}.mw-parser-output table.clade:hover span.linkA{background-color:yellow}.mw-parser-output table.clade:hover span.linkB{background-color:green}</style><table class="clade" style="font-size:90%;line-height:110%"><tbody><tr><td rowspan="2" class="clade-leaf reverse">
<p><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"></p>
<table class="clade"><tbody><tr><td rowspan="2" class="clade-leaf reverse">
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"><table class="clade"><tbody><tr><td rowspan="2" class="clade-leaf reverse">
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"><table class="clade"><tbody><tr><td rowspan="2" class="clade-leaf reverse">
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"><table class="clade"><tbody><tr><td rowspan="2" class="clade-leaf reverse">
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"><table class="clade"><tbody><tr><td rowspan="2" class="clade-leaf reverse">
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"><table class="clade"><tbody><tr><td rowspan="2" class="clade-leaf reverse">
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"><table class="clade"><tbody><tr><td rowspan="2" class="clade-leaf reverse">
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"><table class="clade"><tbody><tr><td rowspan="2" class="clade-leaf reverse">
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"><table class="clade"><tbody><tr><td rowspan="2" class="clade-leaf reverse">
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"><table class="clade"><tbody><tr><td rowspan="2" class="clade-leaf reverse">
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"><table class="clade"><tbody><tr><td rowspan="2" class="clade-leaf reverse">
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"><table class="clade"><tbody><tr><td rowspan="2" class="clade-leaf reverse">
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"><table class="clade"><tbody><tr><td rowspan="2" class="clade-leaf reverse">
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"><table class="clade"><tbody><tr><td rowspan="2" class="clade-leaf reverse">
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"><table class="clade"><tbody><tr><td rowspan="2" class="clade-leaf reverse">
<p>Gilead Sciences
</p>
</td>
<td class="clade-label first"> 
</td></tr><tr><td class="clade-slabel reverse"> 
</td></tr><tr><td rowspan="2" class="clade-leaf reverse">
<p>NeXstar Pharmaceuticals<br><small>(Acq 1999)</small>
</p>
</td>
<td class="clade-label reverse"> 
</td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td>
<td class="clade-label first"> 
</td></tr><tr><td class="clade-slabel reverse"> 
</td></tr><tr><td rowspan="2" class="clade-leaf reverse">
<p>Triangle Pharmaceuticals<br><small>(Acq 2003)</small>
</p>
</td>
<td class="clade-label reverse"> 
</td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td>
<td class="clade-label first"> 
</td></tr><tr><td class="clade-slabel reverse"> 
</td></tr><tr><td rowspan="2" class="clade-leaf reverse">
<p><a href="/w/index.php?title=Myogen,_Inc.&amp;action=edit&amp;redlink=1" class="new" title="Myogen, Inc. (page does not exist)">Myogen, Inc.</a> <br><small>(Acq 2006)</small>
</p>
</td>
<td class="clade-label reverse"> 
</td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td>
<td class="clade-label first"> 
</td></tr><tr><td class="clade-slabel reverse"> 
</td></tr><tr><td rowspan="2" class="clade-leaf reverse">
<p>Corus Pharma, Inc<br><small>(Acq 2006)</small>
</p>
</td>
<td class="clade-label reverse"> 
</td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td>
<td class="clade-label first"> 
</td></tr><tr><td class="clade-slabel reverse"> 
</td></tr><tr><td rowspan="2" class="clade-leaf reverse">
<p>Raylo Chemicals<br><small>(Acq 2006)</small>
</p>
</td>
<td class="clade-label reverse"> 
</td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td>
<td class="clade-label first"> 
</td></tr><tr><td class="clade-slabel reverse"> 
</td></tr><tr><td rowspan="2" class="clade-leaf reverse">
<p>CV Therapeutics, Inc.<br><small>(Acq 2009)</small>
</p>
</td>
<td class="clade-label reverse"> 
</td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td>
<td class="clade-label first"> 
</td></tr><tr><td class="clade-slabel reverse"> 
</td></tr><tr><td rowspan="2" class="clade-leaf reverse">
<p>CGI Pharmaceuticals<br><small>(Acq 2010)</small>
</p>
</td>
<td class="clade-label reverse"> 
</td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td>
<td class="clade-label first"> 
</td></tr><tr><td class="clade-slabel reverse"> 
</td></tr><tr><td rowspan="2" class="clade-leaf reverse">
<p>Calistoga Pharmaceuticals <small>(Acq 2011)</small>
</p>
</td>
<td class="clade-label reverse"> 
</td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td>
<td class="clade-label first"> 
</td></tr><tr><td class="clade-slabel reverse"> 
</td></tr><tr><td rowspan="2" class="clade-leaf reverse">
<p><a href="/wiki/Pharmasset" title="Pharmasset">Pharmasset</a> Inc<br><small>(Acq 2011)</small>
</p>
</td>
<td class="clade-label reverse"> 
</td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td>
<td class="clade-label first"> 
</td></tr><tr><td class="clade-slabel reverse"> 
</td></tr><tr><td rowspan="2" class="clade-leaf reverse">
<p>Phenex Pharmaceuticals<br><small>(Acq 2015)</small>
</p>
</td>
<td class="clade-label reverse"> 
</td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td>
<td class="clade-label first"> 
</td></tr><tr><td class="clade-slabel reverse"> 
</td></tr><tr><td rowspan="2" class="clade-leaf reverse">
<p>EpiTherapeutics<br><small>(Acq 2015)</small>
</p>
</td>
<td class="clade-label reverse"> 
</td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td>
<td class="clade-label first"> 
</td></tr><tr><td class="clade-slabel reverse"> 
</td></tr><tr><td rowspan="2" class="clade-leaf reverse">
<p>Galapagos NV<br><small>(Acq 2015)</small>
</p>
</td>
<td class="clade-label reverse"> 
</td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td>
<td class="clade-label first"> 
</td></tr><tr><td class="clade-slabel reverse"> 
</td></tr><tr><td rowspan="2" class="clade-leaf reverse">
<p>Nimbus Apollo, Inc.<br><small>(Acq 2016)</small>
</p>
</td>
<td class="clade-label reverse"> 
</td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td>
<td class="clade-label first"> 
</td></tr><tr><td class="clade-slabel reverse"> 
</td></tr><tr><td rowspan="2" class="clade-leaf reverse">
<p><a href="/wiki/Kite_Pharma" title="Kite Pharma">Kite Pharma</a><br><small>(Acq 2017)</small>
</p>
</td>
<td class="clade-label reverse"> 
</td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td>
<td class="clade-label first"> 
</td></tr><tr><td class="clade-slabel reverse"> 
</td></tr><tr><td rowspan="2" class="clade-leaf reverse">
<p>Cell Design Labs<br><small>(Acq 2017)</small>
</p>
</td>
<td class="clade-label reverse"> 
</td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td>
<td class="clade-label first" style="border-left:none;border-right:none;border-bottom:0px solid;"><div style="display:inline;" class="nowrap"><span style="font-size:100%;"><b>Gilead Sciences</b></span></div>
</td></tr><tr><td class="clade-slabel last" style="border-right:none;border-left:none;"> 
</td></tr></tbody></table></div></div>
</section><h2 class="section-heading" onclick="javascript:mfTempOpenSection(2)"><div class="mw-ui-icon mw-ui-icon-element indicator mw-ui-icon-small mw-ui-icon-flush-left"></div><span class="mw-headline" id="Criticism">Criticism</span><span class="mw-editsection"><a href="/w/index.php?title=Gilead_Sciences&amp;action=edit&amp;section=11" title="Edit section: Criticism" data-section="11" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h2><section class="mf-section-2 collapsible-block" id="mf-section-2">
<p>Several class-action lawsuits have been filed against Gilead over allegations that the company deliberately delayed development of antiretroviral drugs based on <a href="/wiki/Tenofovir_alafenamide" title="Tenofovir alafenamide">tenofovir alafenamide fumarate (TAF)</a> in order to maximize profits from previous-generation medications containing <a href="/wiki/Tenofovir_disoproxil" title="Tenofovir disoproxil">tenofovir disoproxil fumarate (TDF)</a>.<sup id="cite_ref-65" class="reference"><a href="#cite_note-65">[65]</a></sup> Plaintiffs allege that Gilead suspended TAF in 2004 despite clear evidence indicating that TAF-based medications were safer than TDF, a compound whose long-term use was associated with adverse side effects such as <a href="/wiki/Nephrotoxicity" title="Nephrotoxicity">nephrotoxicity</a> and <a href="/wiki/Bone_density" title="Bone density">bone density</a> loss.<sup id="cite_ref-66" class="reference"><a href="#cite_note-66">[66]</a></sup><sup id="cite_ref-67" class="reference"><a href="#cite_note-67">[67]</a></sup> Gilead intentionally withheld results of clinical trials demonstrating TAF's relative safety and efficacy and shelved TAF-based therapies until 2010, when the <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> approved Gilead's application to patent TAF.<sup id="cite_ref-68" class="reference"><a href="#cite_note-68">[68]</a></sup> Gilead's first TAF medication, marketed under the trade name Genvoya, came out in 2015. In the interim period, many HIV patients who continuously took Gilead's older TDF-based drugs suffered permanent, debilitating kidney and bone damage, often developing conditions such as <a href="/wiki/Fanconi_syndrome" title="Fanconi syndrome">Fanconi syndrome</a> and <a href="/wiki/Osteomalacia" title="Osteomalacia">osteomalacia</a>.<sup id="cite_ref-69" class="reference"><a href="#cite_note-69">[69]</a></sup></p><p>Gilead has come under intense criticism for its high pricing of its patented drug <a href="/wiki/Sofosbuvir" title="Sofosbuvir">sofosbuvir</a>. In the US, for instance, it was launched at $1,000 per pill or $84,000 for the standard 84-day course.<sup class="noprint Inline-Template Template-Fact" style="white-space:nowrap;">[<i><a href="/wiki/Wikipedia:Citation_needed" title="Wikipedia:Citation needed"><span title="This claim needs references to reliable sources. (March 2020)">citation needed</span></a></i>]</sup></p><p>Gilead has also tried to eliminate competition in lucrative markets by entering voluntary licensing agreements (VLA) with companies from developing countries such as India, which mandated the limitation of the latter's operations to less lucrative markets. The company has also been criticized for creating harsh restrictions within countries where they have been denied rights, or are engaged in VLAs. For example, in India, they tried to create an 'anti-diversion' program to determine who could buy the drug, which was considered a coercive and policing move by <a href="/wiki/M%C3%A9decins_Sans_Fronti%C3%A8res" title="Médecins Sans Frontières">Médecins Sans Frontières</a> since it could lead to the exclusion of vulnerable groups like refugees and migrants from accessing the medicines.<sup id="cite_ref-70" class="reference"><a href="#cite_note-70">[70]</a></sup></p><p>On January 21 2020, the <a href="/wiki/Wuhan_Institute_of_Virology" title="Wuhan Institute of Virology">Wuhan Institute of Virology</a> applied for a Chinese "use patent" on <a href="/wiki/Remdesivir" title="Remdesivir">remdesivir</a>, for the novel use of treating <a href="/wiki/COVID-19" class="mw-redirect" title="COVID-19">COVID-19</a>.<sup id="cite_ref-71" class="reference"><a href="#cite_note-71">[71]</a></sup></p><p>Gilead sought and obtained <a href="/wiki/Orphan_Drug_Act_of_1983" title="Orphan Drug Act of 1983">"orphan drug" status</a> for remdesivir from the US <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> on March 23rd, 2020. This provision is intended to encourage the development of drugs affecting fewer than 200,000 Americans by granting strengthened and extended legal monopoly rights to the manufacturer, along with waivers on taxes and government fees.<sup id="cite_ref-rare_72-0" class="reference"><a href="#cite_note-rare-72">[72]</a></sup><sup id="cite_ref-grants_73-0" class="reference"><a href="#cite_note-grants-73">[73]</a></sup> Remdesivir is a candidate for treating COVID-19; at the time the status was granted, fewer than 200,000 Americans had COVID-19, but numbers were climbing rapidly as the <a href="/wiki/COVID-19_pandemic" class="mw-redirect" title="COVID-19 pandemic">COVID-19 pandemic</a> reached the US, and crossing the threshold soon was considered inevitable.<sup id="cite_ref-rare_72-1" class="reference"><a href="#cite_note-rare-72">[72]</a></sup><sup id="cite_ref-grants_73-1" class="reference"><a href="#cite_note-grants-73">[73]</a></sup> Remdesivir was developed by Gilead with over $79 million in U.S. government funding.<sup id="cite_ref-grants_73-2" class="reference"><a href="#cite_note-grants-73">[73]</a></sup> After facing strong reactions, Gilead gave up the "orphan drug" status for remdesivir on March 25th.<sup id="cite_ref-74" class="reference"><a href="#cite_note-74">[74]</a></sup> Gilead retains 20-year remdesivir patents in more than 70 countries.<sup id="cite_ref-75" class="reference"><a href="#cite_note-75">[75]</a></sup></p><p>Gilead has also been accused of price-gouging on other medications developed with public funding, including AIDS <a href="/wiki/PrEP" class="mw-redirect" title="PrEP">PrEP</a> drug <a href="/wiki/Tenofovir" class="mw-redirect" title="Tenofovir">Tenofovir</a> and hepatitis C drug <a href="/wiki/Sofosbuvir" title="Sofosbuvir">Sofosbuvir</a>.<sup id="cite_ref-76" class="reference"><a href="#cite_note-76">[76]</a></sup></p>
</section><h2 class="section-heading" onclick="javascript:mfTempOpenSection(3)"><div class="mw-ui-icon mw-ui-icon-element indicator mw-ui-icon-small mw-ui-icon-flush-left"></div><span class="mw-headline" id="References">References</span><span class="mw-editsection"><a href="/w/index.php?title=Gilead_Sciences&amp;action=edit&amp;section=12" title="Edit section: References" data-section="12" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h2><section class="mf-section-3 collapsible-block" id="mf-section-3">
<div class="reflist columns references-column-width" style="-moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em; list-style-type: decimal;">
<ol class="references"><li id="cite_note-8-K20181210-1"><span class="mw-cite-backlink"><b><a href="#cite_ref-8-K20181210_1-0">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://investors.gilead.com/static-files/5e0529cc-d6b4-47c3-8ea0-3bb0614bfdc9">"Gilead Sciences, Inc. Form 8-K"</a>. <a href="/wiki/U.S._Securities_and_Exchange_Commission" title="U.S. Securities and Exchange Commission">U.S. Securities and Exchange Commission</a>. December 2018.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Gilead+Sciences%2C+Inc.+Form+8-K&amp;rft.pub=U.S.+Securities+and+Exchange+Commission&amp;rft.date=2018-12&amp;rft_id=http%3A%2F%2Finvestors.gilead.com%2Fstatic-files%2F5e0529cc-d6b4-47c3-8ea0-3bb0614bfdc9&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><style data-mw-deduplicate="TemplateStyles:r935243608">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}</style></span>
</li>
<li id="cite_note-10-K-2"><span class="mw-cite-backlink">^ <a href="#cite_ref-10-K_2-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-10-K_2-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-10-K_2-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-10-K_2-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-10-K_2-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-10-K_2-5"><sup><i><b>f</b></i></sup></a></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.sec.gov/Archives/edgar/data/882095/000088209519000006/a2018form10-k.htm">"Gilead Sciences, Inc. 2018 Annual Report (Form 10-K)"</a>. <i>sec.gov</i>. <a href="/wiki/U.S._Securities_and_Exchange_Commission" title="U.S. Securities and Exchange Commission">U.S. Securities and Exchange Commission</a>. March 2019.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=sec.gov&amp;rft.atitle=Gilead+Sciences%2C+Inc.+2018+Annual+Report+%28Form+10-K%29&amp;rft.date=2019-03&amp;rft_id=https%3A%2F%2Fwww.sec.gov%2FArchives%2Fedgar%2Fdata%2F882095%2F000088209519000006%2Fa2018form10-k.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-3"><span class="mw-cite-backlink"><b><a href="#cite_ref-3">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://craft.co/gilead-sciences">"Gilead Sciences Company Profile"</a>. <i>craft.co</i><span class="reference-accessdate">. Retrieved <span class="nowrap">October 8,</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=craft.co&amp;rft.atitle=Gilead+Sciences+Company+Profile&amp;rft_id=https%3A%2F%2Fcraft.co%2Fgilead-sciences&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-Tansey-4"><span class="mw-cite-backlink">^ <a href="#cite_ref-Tansey_4-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Tansey_4-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Tansey_4-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Tansey_4-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Tansey_4-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-Tansey_4-5"><sup><i><b>f</b></i></sup></a></span> <span class="reference-text"><cite class="citation news">Tansey, Bernadette (April 14, 2003). <a rel="nofollow" class="external text" href="https://www.sfgate.com/business/article/PROFILE-Gilead-Sciences-Gilead-grows-up-2655081.php">"Profile: Gilead Sciences / Gilead grows up / Visionary biotech startup matures into pragmatic industry leader"</a>. <i>San Francisco Chronicle</i>. Hearst Communications, Inc. p. E1<span class="reference-accessdate">. Retrieved <span class="nowrap">March 21,</span> 2020</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=San+Francisco+Chronicle&amp;rft.atitle=Profile%3A+Gilead+Sciences+%2F+Gilead+grows+up+%2F+Visionary+biotech+startup+matures+into+pragmatic+industry+leader&amp;rft.pages=E1&amp;rft.date=2003-04-14&amp;rft.aulast=Tansey&amp;rft.aufirst=Bernadette&amp;rft_id=https%3A%2F%2Fwww.sfgate.com%2Fbusiness%2Farticle%2FPROFILE-Gilead-Sciences-Gilead-grows-up-2655081.php&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-boslaugh-5"><span class="mw-cite-backlink">^ <a href="#cite_ref-boslaugh_5-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-boslaugh_5-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-boslaugh_5-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><cite class="citation book">Boslaugh, Sarah E. (September 15, 2015). <a rel="nofollow" class="external text" href="https://books.google.com/?id=du8BCwAAQBAJ&amp;pg=PA657"><i>The SAGE Encyclopedia of Pharmacology and Society</i></a>. SAGE Publications. p. 657. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a> <a href="/wiki/Special:BookSources/978-1-4833-4999-2" title="Special:BookSources/978-1-4833-4999-2"><bdi>978-1-4833-4999-2</bdi></a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=The+SAGE+Encyclopedia+of+Pharmacology+and+Society&amp;rft.pages=657&amp;rft.pub=SAGE+Publications&amp;rft.date=2015-09-15&amp;rft.isbn=978-1-4833-4999-2&amp;rft.aulast=Boslaugh&amp;rft.aufirst=Sarah+E.&amp;rft_id=https%3A%2F%2Fbooks.google.com%2F%3Fid%3Ddu8BCwAAQBAJ%26pg%3DPA657&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-6"><span class="mw-cite-backlink"><b><a href="#cite_ref-6">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://web.archive.org/web/20140821175910/http://engineering.wustl.edu/alumniawards.aspx?year=1996">"1996 Alumni Achievement Awards"</a>. Washington University in St. Louis. Archived from <a rel="nofollow" class="external text" href="http://engineering.wustl.edu/alumniawards.aspx?year=1996">the original</a> on August 21, 2014.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=1996+Alumni+Achievement+Awards&amp;rft.pub=Washington+University+in+St.+Louis&amp;rft_id=http%3A%2F%2Fengineering.wustl.edu%2Falumniawards.aspx%3Fyear%3D1996&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-7"><span class="mw-cite-backlink"><b><a href="#cite_ref-7">^</a></b></span> <span class="reference-text"><cite class="citation news">Moukheiber, Kerry A. Dolan Zina. <a rel="nofollow" class="external text" href="https://www.forbes.com/global/2003/1027/090.html#1c843b13753b">"The Golden Age of Antiviral Drugs"</a>. <i>Forbes</i><span class="reference-accessdate">. Retrieved <span class="nowrap">December 14,</span> 2017</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Forbes&amp;rft.atitle=The+Golden+Age+of+Antiviral+Drugs&amp;rft.aulast=Moukheiber&amp;rft.aufirst=Kerry+A.+Dolan+Zina&amp;rft_id=https%3A%2F%2Fwww.forbes.com%2Fglobal%2F2003%2F1027%2F090.html%231c843b13753b&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-8"><span class="mw-cite-backlink"><b><a href="#cite_ref-8">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.scribd.com/document/109025550/Gilead-Sciences-Board-Resolution-Michael-Riordan-Founder-CEO-Chairman-Antiviral-Medicine-AIDS-Therapeutics-Nucleotides">"Gilead Sciences Board Resolution Michael Riordan Founder CEO Chairman Antiviral Medicine AIDS Therapeutics Nucleotides"</a>. <i>Scribd</i><span class="reference-accessdate">. Retrieved <span class="nowrap">December 14,</span> 2017</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Scribd&amp;rft.atitle=Gilead+Sciences+Board+Resolution+Michael+Riordan+Founder+CEO+Chairman+Antiviral+Medicine+AIDS+Therapeutics+Nucleotides&amp;rft_id=https%3A%2F%2Fwww.scribd.com%2Fdocument%2F109025550%2FGilead-Sciences-Board-Resolution-Michael-Riordan-Founder-CEO-Chairman-Antiviral-Medicine-AIDS-Therapeutics-Nucleotides&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-auto-9"><span class="mw-cite-backlink"><b><a href="#cite_ref-auto_9-0">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.fundinguniverse.com/company-histories/gilead-sciences-inc-history/">"History of Gilead Sciences, Inc. – FundingUniverse"</a>. <i>fundinguniverse.com</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=fundinguniverse.com&amp;rft.atitle=History+of+Gilead+Sciences%2C+Inc.+%E2%80%93+FundingUniverse&amp;rft_id=http%3A%2F%2Fwww.fundinguniverse.com%2Fcompany-histories%2Fgilead-sciences-inc-history%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-10"><span class="mw-cite-backlink"><b><a href="#cite_ref-10">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.nih.gov/about-nih/what-we-do/nih-almanac/harold-e-varmus-md">"Harold E. Varmus, M.D."</a> <i>National Institutes of Health (NIH)</i>. August 6, 2015<span class="reference-accessdate">. Retrieved <span class="nowrap">February 25,</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=National+Institutes+of+Health+%28NIH%29&amp;rft.atitle=Harold+E.+Varmus%2C+M.D.&amp;rft.date=2015-08-06&amp;rft_id=https%3A%2F%2Fwww.nih.gov%2Fabout-nih%2Fwhat-we-do%2Fnih-almanac%2Fharold-e-varmus-md&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-11"><span class="mw-cite-backlink"><b><a href="#cite_ref-11">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.nobelprize.org/prizes/medicine/2009/press-release/">"The Nobel Prize in Physiology or Medicine 2009"</a>. <i>NobelPrize.org</i><span class="reference-accessdate">. Retrieved <span class="nowrap">February 25,</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=NobelPrize.org&amp;rft.atitle=The+Nobel+Prize+in+Physiology+or+Medicine+2009&amp;rft_id=https%3A%2F%2Fwww.nobelprize.org%2Fprizes%2Fmedicine%2F2009%2Fpress-release%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-12"><span class="mw-cite-backlink"><b><a href="#cite_ref-12">^</a></b></span> <span class="reference-text"><cite class="citation news">Moukheiber, Zina; Dolan, Kerry A. (October 27, 2003). <a rel="nofollow" class="external text" href="https://www.forbes.com/global/2003/1027/090.html">"The Golden Age of Antiviral Drugs"</a>. <i>Forbes</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Forbes&amp;rft.atitle=The+Golden+Age+of+Antiviral+Drugs&amp;rft.date=2003-10-27&amp;rft.aulast=Moukheiber&amp;rft.aufirst=Zina&amp;rft.au=Dolan%2C+Kerry+A.&amp;rft_id=https%3A%2F%2Fwww.forbes.com%2Fglobal%2F2003%2F1027%2F090.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-Jacobs-13"><span class="mw-cite-backlink">^ <a href="#cite_ref-Jacobs_13-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Jacobs_13-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Jacobs_13-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Jacobs_13-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Jacobs_13-4"><sup><i><b>e</b></i></sup></a></span> <span class="reference-text"><cite class="citation news">Jacobs, Paul (April 5, 2004). "Gilead Gets Well - Tough Medicine Works At Biotech Firm". <i>San Jose Mercury News</i>. San Jose: Knight Ridder. p. 1F.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=San+Jose+Mercury+News&amp;rft.atitle=Gilead+Gets+Well+-+Tough+Medicine+Works+At+Biotech+Firm&amp;rft.pages=1F&amp;rft.date=2004-04-05&amp;rft.aulast=Jacobs&amp;rft.aufirst=Paul&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"> Available through <a href="/wiki/NewsBank" title="NewsBank">NewsBank</a>.</span>
</li>
<li id="cite_note-14"><span class="mw-cite-backlink"><b><a href="#cite_ref-14">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.ktvq.com/cnn-national/2019/06/27/donald-rumsfeld-fast-facts/">"Donald Rumsfeld Fast Facts"</a>. <i>KTVQ</i>. June 27, 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">April 3,</span> 2020</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=KTVQ&amp;rft.atitle=Donald+Rumsfeld+Fast+Facts&amp;rft.date=2019-06-27&amp;rft_id=https%3A%2F%2Fwww.ktvq.com%2Fcnn-national%2F2019%2F06%2F27%2Fdonald-rumsfeld-fast-facts%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-15"><span class="mw-cite-backlink"><b><a href="#cite_ref-15">^</a></b></span> <span class="reference-text"><cite class="citation web">August 4; 2016. <a rel="nofollow" class="external text" href="https://www.healio.com/infectious-disease/influenza/news/online/%7Bdd9e36ad-b85a-4f58-a843-1c542c771c70%7D/fda-approves-first-generic-of-tamiflu-for-influenza-a-b">"FDA approves first generic of Tamiflu for influenza A, B"</a>. <i>www.healio.com</i><span class="reference-accessdate">. Retrieved <span class="nowrap">April 3,</span> 2020</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.healio.com&amp;rft.atitle=FDA+approves+first+generic+of+Tamiflu+for+influenza+A%2C+B&amp;rft.au=August+4&amp;rft.au=2016&amp;rft_id=https%3A%2F%2Fwww.healio.com%2Finfectious-disease%2Finfluenza%2Fnews%2Fonline%2F%257Bdd9e36ad-b85a-4f58-a843-1c542c771c70%257D%2Ffda-approves-first-generic-of-tamiflu-for-influenza-a-b&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-Abate-16"><span class="mw-cite-backlink">^ <a href="#cite_ref-Abate_16-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Abate_16-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation news">Abate, Tom (August 23, 1999). "Gilead's Success, Pipeline Has Been a Balm for Biotech Investors - Foster City firm's shares have jumped 250% in past year". <i>San Francisco Business Journal</i>. San Francisco: American City Business Journals. p. C1.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=San+Francisco+Business+Journal&amp;rft.atitle=Gilead%27s+Success%2C+Pipeline+Has+Been+a+Balm+for+Biotech+Investors+-+Foster+City+firm%27s+shares+have+jumped+250%25+in+past+year&amp;rft.pages=C1&amp;rft.date=1999-08-23&amp;rft.aulast=Abate&amp;rft.aufirst=Tom&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"> Available through <a href="/wiki/NewsBank" title="NewsBank">NewsBank</a>.</span>
</li>
<li id="cite_note-17"><span class="mw-cite-backlink"><b><a href="#cite_ref-17">^</a></b></span> <span class="reference-text"><cite class="citation journal">Masho, Saba Woldemichael; Wang, Cun-Lin; Nixon, Daniel E (December 2007). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2387297">"Review of tenofovir-emtricitabine"</a>. <i>Therapeutics and Clinical Risk Management</i>. <b>3</b> (6): 1097–1104. <a href="/wiki/International_Standard_Serial_Number" title="International Standard Serial Number">ISSN</a> <a rel="nofollow" class="external text" href="//www.worldcat.org/issn/1176-6336">1176-6336</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a> <span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2387297">2387297</a></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a> <a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/18516268">18516268</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Therapeutics+and+Clinical+Risk+Management&amp;rft.atitle=Review+of+tenofovir-emtricitabine&amp;rft.volume=3&amp;rft.issue=6&amp;rft.pages=1097-1104&amp;rft.date=2007-12&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2387297&amp;rft.issn=1176-6336&amp;rft_id=info%3Apmid%2F18516268&amp;rft.aulast=Masho&amp;rft.aufirst=Saba+Woldemichael&amp;rft.au=Wang%2C+Cun-Lin&amp;rft.au=Nixon%2C+Daniel+E&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2387297&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-LAT2002-18"><span class="mw-cite-backlink">^ <a href="#cite_ref-LAT2002_18-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-LAT2002_18-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation news">Gellene, Denise (December 5, 2002). <a rel="nofollow" class="external text" href="http://articles.latimes.com/2002/dec/05/business/fi-gilead5">"Gilead Sciences to Buy Triangle Pharmaceuticals"</a>. <i>Los Angeles Times</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Los+Angeles+Times&amp;rft.atitle=Gilead+Sciences+to+Buy+Triangle+Pharmaceuticals&amp;rft.date=2002-12-05&amp;rft.aulast=Gellene&amp;rft.aufirst=Denise&amp;rft_id=http%3A%2F%2Farticles.latimes.com%2F2002%2Fdec%2F05%2Fbusiness%2Ffi-gilead5&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-19"><span class="mw-cite-backlink"><b><a href="#cite_ref-19">^</a></b></span> <span class="reference-text"><cite class="citation news"><a rel="nofollow" class="external text" href="https://www.wsj.com/articles/SB1039013783682043153">"Gilead to Pay $464 Million For Triangle Pharmaceuticals"</a>. <i>Wall Street Journal</i>. December 4, 2002.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Wall+Street+Journal&amp;rft.atitle=Gilead+to+Pay+%24464+Million+For+Triangle+Pharmaceuticals&amp;rft.date=2002-12-04&amp;rft_id=https%3A%2F%2Fwww.wsj.com%2Farticles%2FSB1039013783682043153&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-Stanton-20"><span class="mw-cite-backlink"><b><a href="#cite_ref-Stanton_20-0">^</a></b></span> <span class="reference-text"><cite class="citation news">Stanton, Dan (May 20, 2015). <a rel="nofollow" class="external text" href="https://www.outsourcing-pharma.com/Article/2015/05/21/Gilead-s-reliance-on-CMOs-gives-firm-flexibility-says-CFO">"Gilead's reliance on CMOs gives firm 'flexibility' says CFO"</a>. <i>Outsourcing-Pharma.com</i>. Crawley: William Reed Business Media Ltd<span class="reference-accessdate">. Retrieved <span class="nowrap">April 1,</span> 2020</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Outsourcing-Pharma.com&amp;rft.atitle=Gilead%27s+reliance+on+CMOs+gives+firm+%27flexibility%27+says+CFO&amp;rft.date=2015-05-20&amp;rft.aulast=Stanton&amp;rft.aufirst=Dan&amp;rft_id=https%3A%2F%2Fwww.outsourcing-pharma.com%2FArticle%2F2015%2F05%2F21%2FGilead-s-reliance-on-CMOs-gives-firm-flexibility-says-CFO&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-21"><span class="mw-cite-backlink"><b><a href="#cite_ref-21">^</a></b></span> <span class="reference-text">Citation needed; PEP protocol not established years. Sentence reads like they intended for drug to be used for PEP; this was not the case.</span>
</li>
<li id="cite_note-22"><span class="mw-cite-backlink"><b><a href="#cite_ref-22">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://clinicaltrials.gov/ct/search?term=darusentan&amp;submit=Search">"ClinicalTrials.gov - Information on Clinical Trials and Human Research Studies: Darusentan"</a><span class="reference-accessdate">. Retrieved <span class="nowrap">August 18,</span> 2007</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=ClinicalTrials.gov+-+Information+on+Clinical+Trials+and+Human+Research+Studies%3A+Darusentan&amp;rft_id=http%3A%2F%2Fclinicaltrials.gov%2Fct%2Fsearch%3Fterm%3Ddarusentan%26submit%3DSearch&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-23"><span class="mw-cite-backlink"><b><a href="#cite_ref-23">^</a></b></span> <span class="reference-text"><cite class="citation news">Pollack, Andrew (July 13, 2006). <a rel="nofollow" class="external text" href="https://www.nytimes.com/2006/07/13/business/13drug.html">"F.D.A. Backs AIDS Pill to Be Taken Once a Day"</a>. <i><a href="/wiki/New_York_Times" class="mw-redirect" title="New York Times">New York Times</a></i><span class="reference-accessdate">. Retrieved <span class="nowrap">September 20,</span> 2007</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=New+York+Times&amp;rft.atitle=F.D.A.+Backs+AIDS+Pill+to+Be+Taken+Once+a+Day&amp;rft.date=2006-07-13&amp;rft.aulast=Pollack&amp;rft.aufirst=Andrew&amp;rft_id=https%3A%2F%2Fwww.nytimes.com%2F2006%2F07%2F13%2Fbusiness%2F13drug.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-24"><span class="mw-cite-backlink"><b><a href="#cite_ref-24">^</a></b></span> <span class="reference-text"><cite class="citation pressrelease"><a rel="nofollow" class="external text" href="http://www.gilead.com/pr_881419">"U.S. Food And Drug Administration (FDA) Approves Atripla"</a> (Press release). Gilead Sciences and <a href="/wiki/Bristol-Myers_Squibb" title="Bristol-Myers Squibb">Bristol-Myers Squibb</a>. July 12, 2006<span class="reference-accessdate">. Retrieved <span class="nowrap">December 15,</span> 2007</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=U.S.+Food+And+Drug+Administration+%28FDA%29+Approves+Atripla&amp;rft.pub=Gilead+Sciences+and+Bristol-Myers+Squibb&amp;rft.date=2006-07-12&amp;rft_id=http%3A%2F%2Fwww.gilead.com%2Fpr_881419&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-25"><span class="mw-cite-backlink"><b><a href="#cite_ref-25">^</a></b></span> <span class="reference-text"><cite class="citation pressrelease"><a rel="nofollow" class="external text" href="http://www.gilead.com/wt/sec/pr_926645">"Gilead Sciences Completes Acquisition of Raylo Chemicals Inc"</a> (Press release). Gilead Sciences. November 3, 2006<span class="reference-accessdate">. Retrieved <span class="nowrap">June 7,</span> 2007</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Gilead+Sciences+Completes+Acquisition+of+Raylo+Chemicals+Inc.&amp;rft.pub=Gilead+Sciences&amp;rft.date=2006-11-03&amp;rft_id=http%3A%2F%2Fwww.gilead.com%2Fwt%2Fsec%2Fpr_926645&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-26"><span class="mw-cite-backlink"><b><a href="#cite_ref-26">^</a></b></span> <span class="reference-text"><cite class="citation pressrelease"><a rel="nofollow" class="external text" href="http://www.gilead.com/pr_1040975">"Parion Sciences and Gilead Sciences Sign Agreement to Advance Drug Candidates for Pulmonary Disease"</a> (Press release). Gilead Sciences. August 15, 2007<span class="reference-accessdate">. Retrieved <span class="nowrap">August 15,</span> 2007</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Parion+Sciences+and+Gilead+Sciences+Sign+Agreement+to+Advance+Drug+Candidates+for+Pulmonary+Disease&amp;rft.pub=Gilead+Sciences&amp;rft.date=2007-08-15&amp;rft_id=http%3A%2F%2Fwww.gilead.com%2Fpr_1040975&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-:0-27"><span class="mw-cite-backlink">^ <a href="#cite_ref-:0_27-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-:0_27-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text">Reuters, via the New York Times. March 12, 2009. <a rel="nofollow" class="external text" href="https://www.nytimes.com/2009/03/13/business/13biotech.html?_r=0">Gilead, a White Knight, to Buy CV Therapeutics</a></span>
</li>
<li id="cite_note-28"><span class="mw-cite-backlink"><b><a href="#cite_ref-28">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://archive.fortune.com/magazines/fortune/fortunefastestgrowing/2009/full_list/">"100 Fastest-Growing Companies 2009 - from FORTUNE"</a>. <i>archive.fortune.com</i><span class="reference-accessdate">. Retrieved <span class="nowrap">April 13,</span> 2020</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=archive.fortune.com&amp;rft.atitle=100+Fastest-Growing+Companies+2009+-+from+FORTUNE&amp;rft_id=https%3A%2F%2Farchive.fortune.com%2Fmagazines%2Ffortune%2Ffortunefastestgrowing%2F2009%2Ffull_list%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-29"><span class="mw-cite-backlink"><b><a href="#cite_ref-29">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.cnbc.com/id/32389767">"Fortune 100 Fastest-Growing Companies"</a>. <i>www.cnbc.com</i>. August 17, 2009<span class="reference-accessdate">. Retrieved <span class="nowrap">April 13,</span> 2020</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.cnbc.com&amp;rft.atitle=Fortune+100+Fastest-Growing+Companies&amp;rft.date=2009-08-17&amp;rft_id=https%3A%2F%2Fwww.cnbc.com%2Fid%2F32389767&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-30"><span class="mw-cite-backlink"><b><a href="#cite_ref-30">^</a></b></span> <span class="reference-text"><cite class="citation pressrelease"><a rel="nofollow" class="external text" href="http://www.gilead.com/pr_1509319">"Gilead Sciences to Acquire Arresto Biosciences for $225 Million; Deal Adds Pipeline Candidates for Fibrotic Diseases"</a> (Press release). Gilead Sciences. December 20, 2010<span class="reference-accessdate">. Retrieved <span class="nowrap">January 15,</span> 2011</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Gilead+Sciences+to+Acquire+Arresto+Biosciences+for+%24225+Million%3B+Deal+Adds+Pipeline+Candidates+for+Fibrotic+Diseases&amp;rft.pub=Gilead+Sciences&amp;rft.date=2010-12-20&amp;rft_id=http%3A%2F%2Fwww.gilead.com%2Fpr_1509319&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-31"><span class="mw-cite-backlink"><b><a href="#cite_ref-31">^</a></b></span> <span class="reference-text"><cite class="citation pressrelease"><a rel="nofollow" class="external text" href="http://investors.gilead.com/preview/phoenix.zhtml?c=69964&amp;p=irol-newsArticle&amp;ID=1531190&amp;highlight=">"Gilead Sciences to Acquire Calistoga Pharmaceuticals for $375 Million; Deal Adds Pipeline Candidates in Oncology and Inflammation --"</a> (Press release). Gilead Sciences. February 22, 2011<span class="reference-accessdate">. Retrieved <span class="nowrap">February 22,</span> 2011</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Gilead+Sciences+to+Acquire+Calistoga+Pharmaceuticals+for+%24375+Million%3B+Deal+Adds+Pipeline+Candidates+in+Oncology+and+Inflammation+--&amp;rft.pub=Gilead+Sciences&amp;rft.date=2011-02-22&amp;rft_id=http%3A%2F%2Finvestors.gilead.com%2Fpreview%2Fphoenix.zhtml%3Fc%3D69964%26p%3Dirol-newsArticle%26ID%3D1531190%26highlight%3D&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-Leuty-32"><span class="mw-cite-backlink">^ <a href="#cite_ref-Leuty_32-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Leuty_32-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation news">Leuty, Ron (October 19, 2011). <a rel="nofollow" class="external text" href="https://www.bizjournals.com/sanfrancisco/blog/biotech/2011/10/gilead-expansion-building.html">"Gilead breaking ground on 1st part of massive campus rebuild in Foster City"</a>. <i>San Francisco Business Journal</i>. American City Business Journals<span class="reference-accessdate">. Retrieved <span class="nowrap">March 21,</span> 2020</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=San+Francisco+Business+Journal&amp;rft.atitle=Gilead+breaking+ground+on+1st+part+of+massive+campus+rebuild+in+Foster+City&amp;rft.date=2011-10-19&amp;rft.aulast=Leuty&amp;rft.aufirst=Ron&amp;rft_id=https%3A%2F%2Fwww.bizjournals.com%2Fsanfrancisco%2Fblog%2Fbiotech%2F2011%2F10%2Fgilead-expansion-building.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-33"><span class="mw-cite-backlink"><b><a href="#cite_ref-33">^</a></b></span> <span class="reference-text"><cite class="citation web">Perrone, Matthew. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20120716220630/http://today.msnbc.msn.com/id/48198452/ns/today-today_health/t/fda-approves-first-pill-help-prevent-hiv/#.UARSd_VdDvY">"FDA approves first pill to help prevent HIV"</a>. <i>Today Health</i>. NBC News. Archived from <a rel="nofollow" class="external text" href="http://today.msnbc.msn.com/id/48198452/ns/today-today_health/t/fda-approves-first-pill-help-prevent-hiv/#.UARSd_VdDvY">the original</a> on July 16, 2012<span class="reference-accessdate">. Retrieved <span class="nowrap">July 16,</span> 2012</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Today+Health&amp;rft.atitle=FDA+approves+first+pill+to+help+prevent+HIV&amp;rft.aulast=Perrone&amp;rft.aufirst=Matthew&amp;rft_id=http%3A%2F%2Ftoday.msnbc.msn.com%2Fid%2F48198452%2Fns%2Ftoday-today_health%2Ft%2Ffda-approves-first-pill-help-prevent-hiv%2F%23.UARSd_VdDvY&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-34"><span class="mw-cite-backlink"><b><a href="#cite_ref-34">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.genengnews.com/gen-news-highlights/gilead-to-acquire-phenex-s-fxr-program-for-up-to-470m/81250770/">"Gilead to Acquire Phenex's FXR Program for Up-to-$470M"</a>. <i><a href="/wiki/Mary_Ann_Liebert" title="Mary Ann Liebert">Genetic Engineering and Biotechnology News: GEN</a></i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Genetic+Engineering+and+Biotechnology+News%3A+GEN&amp;rft.atitle=Gilead+to+Acquire+Phenex%27s+FXR+Program+for+Up-to-%24470M&amp;rft_id=http%3A%2F%2Fwww.genengnews.com%2Fgen-news-highlights%2Fgilead-to-acquire-phenex-s-fxr-program-for-up-to-470m%2F81250770%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-35"><span class="mw-cite-backlink"><b><a href="#cite_ref-35">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.genengnews.com/gen-news-highlights/gilead-boosts-cancer-pipeline-with-65m-epitherapeutics-buy/81251237/">"Gilead Boosts Cancer Pipeline With $65M EpiTherapeutics Buy"</a>. <i>Genetic Engineering and Biotechnology News: GEN</i>. May 6, 2015.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Genetic+Engineering+and+Biotechnology+News%3A+GEN&amp;rft.atitle=Gilead+Boosts+Cancer+Pipeline+With+%2465M+EpiTherapeutics+Buy&amp;rft.date=2015-05-06&amp;rft_id=http%3A%2F%2Fwww.genengnews.com%2Fgen-news-highlights%2Fgilead-boosts-cancer-pipeline-with-65m-epitherapeutics-buy%2F81251237%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-36"><span class="mw-cite-backlink"><b><a href="#cite_ref-36">^</a></b></span> <span class="reference-text"><cite class="citation web">N/A, Zack's Market Research. <a rel="nofollow" class="external text" href="https://finance.yahoo.com/news/gilead-gild-collaborates-galapagos-filgotinib-214009221.html">"Gilead (GILD) Collaborates with Galapagos for Filgotinib"</a>. <i>Yahoo Finance</i>. Yahoo/Zack's<span class="reference-accessdate">. Retrieved <span class="nowrap">December 31,</span> 2015</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Yahoo+Finance&amp;rft.atitle=Gilead+%28GILD%29+Collaborates+with+Galapagos+for+Filgotinib&amp;rft.aulast=N%2FA&amp;rft.aufirst=Zack%27s+Market+Research&amp;rft_id=https%3A%2F%2Ffinance.yahoo.com%2Fnews%2Fgilead-gild-collaborates-galapagos-filgotinib-214009221.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-37"><span class="mw-cite-backlink"><b><a href="#cite_ref-37">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://investors.gilead.com/phoenix.zhtml?c=69964&amp;p=irol-newsArticle&amp;ID=2153767#sthash.J8GnM3pl.dpuf">"Gilead - Investors - News Release"</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Gilead+-+Investors+-+News+Release&amp;rft_id=http%3A%2F%2Finvestors.gilead.com%2Fphoenix.zhtml%3Fc%3D69964%26p%3Dirol-newsArticle%26ID%3D2153767%23sthash.J8GnM3pl.dpuf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-38"><span class="mw-cite-backlink"><b><a href="#cite_ref-38">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.parentherald.com/articles/35157/20160406/gilead-sciences-nimbus-drug-acquired-offering-cure-fatty-liver.htm">"Gilead Sciences: Nimbus Drug Acquired, Offering Cure For Fatty Liver"</a>. <i>Parent Herald</i>. April 6, 2016.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Parent+Herald&amp;rft.atitle=Gilead+Sciences%3A+Nimbus+Drug+Acquired%2C+Offering+Cure+For+Fatty+Liver&amp;rft.date=2016-04-06&amp;rft_id=http%3A%2F%2Fwww.parentherald.com%2Farticles%2F35157%2F20160406%2Fgilead-sciences-nimbus-drug-acquired-offering-cure-fatty-liver.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-39"><span class="mw-cite-backlink"><b><a href="#cite_ref-39">^</a></b></span> <span class="reference-text"><cite class="citation news"><a rel="nofollow" class="external text" href="http://fortune.com/2016/06/22/fortune-500-most-charitable-companies/">"The Giving 20: The Most Generous Companies in America"</a>. <i>Fortune</i><span class="reference-accessdate">. Retrieved <span class="nowrap">December 14,</span> 2017</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Fortune&amp;rft.atitle=The+Giving+20%3A+The+Most+Generous+Companies+in+America&amp;rft_id=http%3A%2F%2Ffortune.com%2F2016%2F06%2F22%2Ffortune-500-most-charitable-companies%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-40"><span class="mw-cite-backlink"><b><a href="#cite_ref-40">^</a></b></span> <span class="reference-text"><cite class="citation news"><a rel="nofollow" class="external text" href="https://uk.reuters.com/article/uk-kite-pharma-m-a-gilead-sciences-idUKKCN1B810W">"Gilead to buy Kite for promising cancer therapies in $12 billion deal"</a>. <i>reuters.com</i>. August 28, 2017.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=reuters.com&amp;rft.atitle=Gilead+to+buy+Kite+for+promising+cancer+therapies+in+%2412+billion+deal&amp;rft.date=2017-08-28&amp;rft_id=https%3A%2F%2Fuk.reuters.com%2Farticle%2Fuk-kite-pharma-m-a-gilead-sciences-idUKKCN1B810W&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-41"><span class="mw-cite-backlink"><b><a href="#cite_ref-41">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.fiercepharma.com/pharma/gilead-grabs-kite-for-11-9b-thrusting-itself-to-front-car-t-field">"Growth-hungry Gilead finally pivots from flagging hep C with $12B Kite buy"</a>. <i>fiercepharma.com</i>. August 28, 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">August 29,</span> 2017</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=fiercepharma.com&amp;rft.atitle=Growth-hungry+Gilead+finally+pivots+from+flagging+hep+C+with+%2412B+Kite+buy&amp;rft.date=2017-08-28&amp;rft_id=http%3A%2F%2Fwww.fiercepharma.com%2Fpharma%2Fgilead-grabs-kite-for-11-9b-thrusting-itself-to-front-car-t-field&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-42"><span class="mw-cite-backlink"><b><a href="#cite_ref-42">^</a></b></span> <span class="reference-text"><cite class="citation news"><a rel="nofollow" class="external text" href="https://www.reuters.com/article/us-gilead-sciences-m-a-idUSKBN1E134T">"Gilead to buy Cell Design Labs for up to $567 million"</a>. <i>reuters.com</i>. December 7, 2017.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=reuters.com&amp;rft.atitle=Gilead+to+buy+Cell+Design+Labs+for+up+to+%24567+million&amp;rft.date=2017-12-07&amp;rft_id=https%3A%2F%2Fwww.reuters.com%2Farticle%2Fus-gilead-sciences-m-a-idUSKBN1E134T&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-43"><span class="mw-cite-backlink"><b><a href="#cite_ref-43">^</a></b></span> <span class="reference-text"><cite class="citation news">Jr, Donald G. McNeil (May 9, 2019). <a rel="nofollow" class="external text" href="https://www.nytimes.com/2019/05/09/health/gilead-truvada-hiv-aids.html">"Gilead Will Donate Truvada to U.S. for H.I.V. Prevention"</a>. <i>The New York Times</i>. <a href="/wiki/International_Standard_Serial_Number" title="International Standard Serial Number">ISSN</a> <a rel="nofollow" class="external text" href="//www.worldcat.org/issn/0362-4331">0362-4331</a><span class="reference-accessdate">. Retrieved <span class="nowrap">December 4,</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+New+York+Times&amp;rft.atitle=Gilead+Will+Donate+Truvada+to+U.S.+for+H.I.V.+Prevention&amp;rft.date=2019-05-09&amp;rft.issn=0362-4331&amp;rft.aulast=Jr&amp;rft.aufirst=Donald+G.+McNeil&amp;rft_id=https%3A%2F%2Fwww.nytimes.com%2F2019%2F05%2F09%2Fhealth%2Fgilead-truvada-hiv-aids.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-44"><span class="mw-cite-backlink"><b><a href="#cite_ref-44">^</a></b></span> <span class="reference-text"><cite class="citation news">Jr, Donald G. McNeil (December 3, 2019). <a rel="nofollow" class="external text" href="https://www.nytimes.com/2019/12/03/health/truvada-prep-hiv-gilead.html">"200,000 Uninsured Americans to Get Free H.I.V.-Prevention Drugs"</a>. <i>The New York Times</i>. <a href="/wiki/International_Standard_Serial_Number" title="International Standard Serial Number">ISSN</a> <a rel="nofollow" class="external text" href="//www.worldcat.org/issn/0362-4331">0362-4331</a><span class="reference-accessdate">. Retrieved <span class="nowrap">December 4,</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+New+York+Times&amp;rft.atitle=200%2C000+Uninsured+Americans+to+Get+Free+H.I.V.-Prevention+Drugs&amp;rft.date=2019-12-03&amp;rft.issn=0362-4331&amp;rft.aulast=Jr&amp;rft.aufirst=Donald+G.+McNeil&amp;rft_id=https%3A%2F%2Fwww.nytimes.com%2F2019%2F12%2F03%2Fhealth%2Ftruvada-prep-hiv-gilead.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-45"><span class="mw-cite-backlink"><b><a href="#cite_ref-45">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.biospace.com/article/gilead-buys-forty-seven-for-4-9-billion/">"Gilead to Acquire Immuno-Oncology Company Forty Seven for $4.9 Billion"</a>. <i>BioSpace</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=BioSpace&amp;rft.atitle=Gilead+to+Acquire+Immuno-Oncology+Company+Forty+Seven+for+%244.9+Billion&amp;rft_id=https%3A%2F%2Fwww.biospace.com%2Farticle%2Fgilead-buys-forty-seven-for-4-9-billion%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-46"><span class="mw-cite-backlink"><b><a href="#cite_ref-46">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.biospace.com/article/gilead-to-acquire-forty-seven-for-4-9-billion/">"Gilead to Acquire Forty Seven for $4.9 Billion"</a>. <i>BioSpace</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=BioSpace&amp;rft.atitle=Gilead+to+Acquire+Forty+Seven+for+%244.9+Billion&amp;rft_id=https%3A%2F%2Fwww.biospace.com%2Farticle%2Fgilead-to-acquire-forty-seven-for-4-9-billion%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-47"><span class="mw-cite-backlink"><b><a href="#cite_ref-47">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://uk.reuters.com/article/us-forty-seven-m-a-gilead-sciences-idUKKBN20P1PX">"Gilead buys Forty Seven for $4.9 billion to bolster cancer drug pipeline"</a>. March 2, 2020 – via uk.reuters.com.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Gilead+buys+Forty+Seven+for+%244.9+billion+to+bolster+cancer+drug+pipeline&amp;rft.date=2020-03-02&amp;rft_id=https%3A%2F%2Fuk.reuters.com%2Farticle%2Fus-forty-seven-m-a-gilead-sciences-idUKKBN20P1PX&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-48"><span class="mw-cite-backlink"><b><a href="#cite_ref-48">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://investors.gilead.com/news-releases/news-release-details/gilead-completes-acquisition-forty-seven-inc">"Gilead Completes Acquisition of Forty Seven, Inc"</a>. <i>Gilead Sciences</i><span class="reference-accessdate">. Retrieved <span class="nowrap">April 11,</span> 2020</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Gilead+Sciences&amp;rft.atitle=Gilead+Completes+Acquisition+of+Forty+Seven%2C+Inc.&amp;rft_id=http%3A%2F%2Finvestors.gilead.com%2Fnews-releases%2Fnews-release-details%2Fgilead-completes-acquisition-forty-seven-inc&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-49"><span class="mw-cite-backlink"><b><a href="#cite_ref-49">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.businesswire.com/news/home/20200407005494/en/Gilead-Completes-Acquisition-Forty">"Gilead Completes Acquisition of Forty Seven, Inc"</a>. <i>www.businesswire.com</i>. April 7, 2020<span class="reference-accessdate">. Retrieved <span class="nowrap">April 11,</span> 2020</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.businesswire.com&amp;rft.atitle=Gilead+Completes+Acquisition+of+Forty+Seven%2C+Inc.&amp;rft.date=2020-04-07&amp;rft_id=https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20200407005494%2Fen%2FGilead-Completes-Acquisition-Forty&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-50"><span class="mw-cite-backlink"><b><a href="#cite_ref-50">^</a></b></span> <span class="reference-text"><cite class="citation news"><a rel="nofollow" class="external text" href="https://www.forbes.com/sites/matthewherper/2013/12/31/grading-pharma-in-2013-16-drug-companies-ranked/">"Grading Pharma in 2013"</a>. <i>Forbes</i>. December 31, 2013.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Forbes&amp;rft.atitle=Grading+Pharma+in+2013&amp;rft.date=2013-12-31&amp;rft_id=https%3A%2F%2Fwww.forbes.com%2Fsites%2Fmatthewherper%2F2013%2F12%2F31%2Fgrading-pharma-in-2013-16-drug-companies-ranked%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-51"><span class="mw-cite-backlink"><b><a href="#cite_ref-51">^</a></b></span> <span class="reference-text"><cite class="citation news"><a rel="nofollow" class="external text" href="http://www.streetinsider.com/Analyst+Comments/Gilead+(GILD)+Q4+Sovaldi+Sales+Tracking+at+%2453M+-+Deutsche+Bank/9020948.html">"Q4 Sovaldi Sales Tracking at $53 Million"</a>. Street Insider. January 3, 2014.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Q4+Sovaldi+Sales+Tracking+at+%2453+Million&amp;rft.date=2014-01-03&amp;rft_id=http%3A%2F%2Fwww.streetinsider.com%2FAnalyst%2BComments%2FGilead%2B%28GILD%29%2BQ4%2BSovaldi%2BSales%2BTracking%2Bat%2B%2453M%2B-%2BDeutsche%2BBank%2F9020948.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-52"><span class="mw-cite-backlink"><b><a href="#cite_ref-52">^</a></b></span> <span class="reference-text"><cite class="citation news"><a rel="nofollow" class="external text" href="http://blogs.barrons.com/stockstowatchtoday/2014/01/02/gilead-sciences-sovaldi-to-boost-shares-in-2014-maxim-group-says/">"Stocks to Watch"</a>. Barrons. January 2, 2014.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Stocks+to+Watch&amp;rft.date=2014-01-02&amp;rft_id=http%3A%2F%2Fblogs.barrons.com%2Fstockstowatchtoday%2F2014%2F01%2F02%2Fgilead-sciences-sovaldi-to-boost-shares-in-2014-maxim-group-says%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-53"><span class="mw-cite-backlink"><b><a href="#cite_ref-53">^</a></b></span> <span class="reference-text"><cite class="citation news">Sanger-katz, Margot (August 2, 2014). <a rel="nofollow" class="external text" href="https://www.nytimes.com/2014/08/03/upshot/is-a-1000-pill-really-too-much.html">"Critics Raise Concerns About Sovaldi"</a>. <i>The New York Times</i>. <a href="/wiki/International_Standard_Serial_Number" title="International Standard Serial Number">ISSN</a> <a rel="nofollow" class="external text" href="//www.worldcat.org/issn/0362-4331">0362-4331</a><span class="reference-accessdate">. Retrieved <span class="nowrap">October 4,</span> 2015</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+New+York+Times&amp;rft.atitle=Critics+Raise+Concerns+About+Sovaldi&amp;rft.date=2014-08-02&amp;rft.issn=0362-4331&amp;rft.aulast=Sanger-katz&amp;rft.aufirst=Margot&amp;rft_id=https%3A%2F%2Fwww.nytimes.com%2F2014%2F08%2F03%2Fupshot%2Fis-a-1000-pill-really-too-much.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-Martin_2014-54"><span class="mw-cite-backlink"><b><a href="#cite_ref-Martin_2014_54-0">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://seekingalpha.com/article/2880996-gilead-sciences-gild-ceo-john-martin-on-q4-2014-results-earnings-call-transcript?page=4">"Gilead Q4 2014 Earnings Call"</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Gilead+Q4+2014+Earnings+Call&amp;rft_id=http%3A%2F%2Fseekingalpha.com%2Farticle%2F2880996-gilead-sciences-gild-ceo-john-martin-on-q4-2014-results-earnings-call-transcript%3Fpage%3D4&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-55"><span class="mw-cite-backlink"><b><a href="#cite_ref-55">^</a></b></span> <span class="reference-text"><cite class="citation web">Ketaki Gokhale (December 28, 2015). <a rel="nofollow" class="external text" href="https://www.bloomberg.com/news/articles/2015-12-29/the-price-keeps-falling-for-a-superstar-gilead-drug-in-india">"The same pill that cost $1,000 in the U.S. sold for $4 in India"</a>. Bloomberg.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=The+same+pill+that+cost+%241%2C000+in+the+U.S.+sold+for+%244+in+India&amp;rft.pub=Bloomberg&amp;rft.date=2015-12-28&amp;rft.au=Ketaki+Gokhale&amp;rft_id=https%3A%2F%2Fwww.bloomberg.com%2Fnews%2Farticles%2F2015-12-29%2Fthe-price-keeps-falling-for-a-superstar-gilead-drug-in-india&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-Ke2015-56"><span class="mw-cite-backlink"><b><a href="#cite_ref-Ke2015_56-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Keating GM (2015). "Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C". <i>Drugs</i>. <b>75</b> (6): 675–85. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1007%2Fs40265-015-0381-2">10.1007/s40265-015-0381-2</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a> <a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/25837989">25837989</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Drugs&amp;rft.atitle=Ledipasvir%2FSofosbuvir%3A+a+review+of+its+use+in+chronic+hepatitis+C&amp;rft.volume=75&amp;rft.issue=6&amp;rft.pages=675-85&amp;rft.date=2015&amp;rft_id=info%3Adoi%2F10.1007%2Fs40265-015-0381-2&amp;rft_id=info%3Apmid%2F25837989&amp;rft.aulast=Keating&amp;rft.aufirst=GM&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-57"><span class="mw-cite-backlink"><b><a href="#cite_ref-57">^</a></b></span> <span class="reference-text"><cite class="citation web">Michael Douglass (March 9, 2017). <a rel="nofollow" class="external text" href="https://www.fool.com/investing/2017/03/09/i-was-wrong-about-gilead-sciences.aspx">"I Was Wrong About Gilead Sciences"</a>. The Motley Fool.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=I+Was+Wrong+About+Gilead+Sciences&amp;rft.pub=The+Motley+Fool&amp;rft.date=2017-03-09&amp;rft.au=Michael+Douglass&amp;rft_id=https%3A%2F%2Fwww.fool.com%2Finvesting%2F2017%2F03%2F09%2Fi-was-wrong-about-gilead-sciences.aspx&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-58"><span class="mw-cite-backlink"><b><a href="#cite_ref-58">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.macrotrends.net/stocks/charts/GILD/gilead-sciences/revenue">"Gilead Sciences Revenue 2006-2018 | GILD"</a>. <i>www.macrotrends.net</i><span class="reference-accessdate">. Retrieved <span class="nowrap">November 1,</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.macrotrends.net&amp;rft.atitle=Gilead+Sciences+Revenue+2006-2018+%7C+GILD&amp;rft_id=https%3A%2F%2Fwww.macrotrends.net%2Fstocks%2Fcharts%2FGILD%2Fgilead-sciences%2Frevenue&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-59"><span class="mw-cite-backlink"><b><a href="#cite_ref-59">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.gilead.com/purpose/mission-and-core-values">"Mission &amp; Core Values - Gilead"</a>. <i>www.gilead.com</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.gilead.com&amp;rft.atitle=Mission+%26+Core+Values+-+Gilead&amp;rft_id=https%3A%2F%2Fwww.gilead.com%2Fpurpose%2Fmission-and-core-values&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-60"><span class="mw-cite-backlink"><b><a href="#cite_ref-60">^</a></b></span> <span class="reference-text"><cite class="citation web">Allison Gatlin (April 6, 2017). <a rel="nofollow" class="external text" href="http://www.investors.com/news/technology/will-gileads-hiv-franchise-plan-be-dashed-on-trumpcare/">"Will Gilead's HIV Franchise Plan Be Dashed On TrumpCare?"</a>. Investors Business Daily.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Will+Gilead%27s+HIV+Franchise+Plan+Be+Dashed+On+TrumpCare%3F&amp;rft.pub=Investors+Business+Daily&amp;rft.date=2017-04-06&amp;rft.au=Allison+Gatlin&amp;rft_id=http%3A%2F%2Fwww.investors.com%2Fnews%2Ftechnology%2Fwill-gileads-hiv-franchise-plan-be-dashed-on-trumpcare%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-61"><span class="mw-cite-backlink"><b><a href="#cite_ref-61">^</a></b></span> <span class="reference-text"><cite class="citation web">Ben Levisohn (March 13, 2017). <a rel="nofollow" class="external text" href="http://blogs.barrons.com/stockstowatchtoday/2017/03/13/gilead-sciences-is-an-incyte-deal-reasonable/">"Gilead Sciences: Is an Incyte Deal 'Reasonable'?"</a>. Barron's.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Gilead+Sciences%3A+Is+an+Incyte+Deal+%27Reasonable%27%3F&amp;rft.pub=Barron%27s&amp;rft.date=2017-03-13&amp;rft.au=Ben+Levisohn&amp;rft_id=http%3A%2F%2Fblogs.barrons.com%2Fstockstowatchtoday%2F2017%2F03%2F13%2Fgilead-sciences-is-an-incyte-deal-reasonable%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-62"><span class="mw-cite-backlink"><b><a href="#cite_ref-62">^</a></b></span> <span class="reference-text"><cite class="citation web">Ioannis Stamatopoulos (February 12, 2017). <a rel="nofollow" class="external text" href="http://seekingalpha.com/article/4045199-pharma-m-2017-likely-deal-hunters">"Pharma M&amp;A In 2017: The Most Likely Deal Hunters"</a>. Seeking Alpha<span class="reference-accessdate">. Retrieved <span class="nowrap">March 12,</span> 2017</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Pharma+M%26A+In+2017%3A+The+Most+Likely+Deal+Hunters&amp;rft.pub=Seeking+Alpha&amp;rft.date=2017-02-12&amp;rft.au=Ioannis+Stamatopoulos&amp;rft_id=http%3A%2F%2Fseekingalpha.com%2Farticle%2F4045199-pharma-m-2017-likely-deal-hunters&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-63"><span class="mw-cite-backlink"><b><a href="#cite_ref-63">^</a></b></span> <span class="reference-text"><cite class="citation web">Alison R. Walker (January 1, 2016). <a rel="nofollow" class="external text" href="http://www.bloodjournal.org/content/128/22/2831?sso-checked=true">"Interim Results of a Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination with Chemotherapy in Patients with Acute Myeloid Leukemia"</a>. Blood Journal.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Interim+Results+of+a+Phase+1b%2F2+Study+of+Entospletinib+%28GS-9973%29+Monotherapy+and+in+Combination+with+Chemotherapy+in+Patients+with+Acute+Myeloid+Leukemia&amp;rft.pub=Blood+Journal&amp;rft.date=2016-01-01&amp;rft.au=Alison+R.+Walker&amp;rft_id=http%3A%2F%2Fwww.bloodjournal.org%2Fcontent%2F128%2F22%2F2831%3Fsso-checked%3Dtrue&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-64"><span class="mw-cite-backlink"><b><a href="#cite_ref-64">^</a></b></span> <span class="reference-text"><cite class="citation news">Paul O'Donoghue (December 26, 2018). <a rel="nofollow" class="external text" href="https://www.thetimes.co.uk/article/us-pharma-giant-gilead-uses-double-irish-tax-loophole-j9gq5rdb7">"US pharma giant Gilead uses 'Double Irish' tax loophole"</a>. <i><a href="/wiki/The_Times" title="The Times">The Times</a></i>. London.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Times&amp;rft.atitle=US+pharma+giant+Gilead+uses+%27Double+Irish%27+tax+loophole&amp;rft.date=2018-12-26&amp;rft.au=Paul+O%27Donoghue&amp;rft_id=https%3A%2F%2Fwww.thetimes.co.uk%2Farticle%2Fus-pharma-giant-gilead-uses-double-irish-tax-loophole-j9gq5rdb7&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-65"><span class="mw-cite-backlink"><b><a href="#cite_ref-65">^</a></b></span> <span class="reference-text"><cite id="51" class="citation web">Petersen, Melody (May 5, 2018). <a rel="nofollow" class="external text" href="https://www.latimes.com/business/la-fi-gilead-hiv-drug-lawsuit-20180509-story.html">"Patients sue Gilead, saying drug company intentionally delayed safer HIV medicine"</a>. <i>Los Angeles Times</i><span class="reference-accessdate">. Retrieved <span class="nowrap">December 7,</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Los+Angeles+Times&amp;rft.atitle=Patients+sue+Gilead%2C+saying+drug+company+intentionally+delayed+safer+HIV+medicine&amp;rft.date=2018-05-05&amp;rft.aulast=Petersen&amp;rft.aufirst=Melody&amp;rft_id=https%3A%2F%2Fwww.latimes.com%2Fbusiness%2Fla-fi-gilead-hiv-drug-lawsuit-20180509-story.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-66"><span class="mw-cite-backlink"><b><a href="#cite_ref-66">^</a></b></span> <span class="reference-text"><cite class="citation journal">Tourret, Jérôme; Deray, Gilbert; Isnard-Bagnis, Corinne (2013). <a rel="nofollow" class="external text" href="https://jasn.asnjournals.org/content/24/10/1519">"Tenofovir Effect on the Kidneys of HIV-Infected Patients: A Double-Edged Sword?"</a>. <i>Journal of the American Society of Nephrology</i>. <b>24</b> (10): 1519–1527. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1681%2FASN.2012080857">10.1681/ASN.2012080857</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a> <span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3785270">3785270</a></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a> <a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/24052632">24052632</a><span class="reference-accessdate">. Retrieved <span class="nowrap">December 7,</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+the+American+Society+of+Nephrology&amp;rft.atitle=Tenofovir+Effect+on+the+Kidneys+of+HIV-Infected+Patients%3A+A+Double-Edged+Sword%3F&amp;rft.volume=24&amp;rft.issue=10&amp;rft.pages=1519-1527&amp;rft.date=2013&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3785270&amp;rft_id=info%3Apmid%2F24052632&amp;rft_id=info%3Adoi%2F10.1681%2FASN.2012080857&amp;rft.aulast=Tourret&amp;rft.aufirst=J%C3%A9r%C3%B4me&amp;rft.au=Deray%2C+Gilbert&amp;rft.au=Isnard-Bagnis%2C+Corinne&amp;rft_id=https%3A%2F%2Fjasn.asnjournals.org%2Fcontent%2F24%2F10%2F1519&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-67"><span class="mw-cite-backlink"><b><a href="#cite_ref-67">^</a></b></span> <span class="reference-text"><cite class="citation journal">Grigsby, Iwen F.; Pham, Lan; Mansky, Louis M.; Gopalakrishnan, Raj; Mansky, Kim C. (2010). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2817787">"Tenofovir-associated bone density loss"</a>. <i>Therapeutics and Clinical Risk Management</i>. <b>6</b>: 41–47. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a> <span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2817787">2817787</a></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a> <a rel="nofollow" class="external text" href="//pubmed.ncbi.nlm.nih.gov/20169035">20169035</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Therapeutics+and+Clinical+Risk+Management&amp;rft.atitle=Tenofovir-associated+bone+density+loss&amp;rft.volume=6&amp;rft.pages=41-47&amp;rft.date=2010&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2817787&amp;rft_id=info%3Apmid%2F20169035&amp;rft.aulast=Grigsby&amp;rft.aufirst=Iwen+F.&amp;rft.au=Pham%2C+Lan&amp;rft.au=Mansky%2C+Louis+M.&amp;rft.au=Gopalakrishnan%2C+Raj&amp;rft.au=Mansky%2C+Kim+C.&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2817787&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-68"><span class="mw-cite-backlink"><b><a href="#cite_ref-68">^</a></b></span> <span class="reference-text"><cite class="citation web">Rowland, Christopher (December 5, 2019). <a rel="nofollow" class="external text" href="https://www.washingtonpost.com/business/economy/gilead-delayed-safer-hiv-drug-to-extend-monopoly-profits-advocates-allege/2019/12/05/71d4d6ae-1538-11ea-8406-df3c54b3253e_story.html">"Gilead delayed safer HIV drug to extend monopoly profits, advocates allege"</a>. <i>Washington Post</i><span class="reference-accessdate">. Retrieved <span class="nowrap">December 7,</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Washington+Post&amp;rft.atitle=Gilead+delayed+safer+HIV+drug+to+extend+monopoly+profits%2C+advocates+allege&amp;rft.date=2019-12-05&amp;rft.aulast=Rowland&amp;rft.aufirst=Christopher&amp;rft_id=https%3A%2F%2Fwww.washingtonpost.com%2Fbusiness%2Feconomy%2Fgilead-delayed-safer-hiv-drug-to-extend-monopoly-profits-advocates-allege%2F2019%2F12%2F05%2F71d4d6ae-1538-11ea-8406-df3c54b3253e_story.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-69"><span class="mw-cite-backlink"><b><a href="#cite_ref-69">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.businesswire.com/news/home/20190411005808/en/">"Gilead Lawsuits: 41 HIV and PrEP Patients File California Personal Injury Case Over Gilead's TDF-Based Drugs"</a>. <i>Business Wire</i>. April 11, 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">December 7,</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Business+Wire&amp;rft.atitle=Gilead+Lawsuits%3A+41+HIV+and+PrEP+Patients+File+California+Personal+Injury+Case+Over+Gilead%27s+TDF-Based+Drugs&amp;rft.date=2019-04-11&amp;rft_id=https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20190411005808%2Fen%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-70"><span class="mw-cite-backlink"><b><a href="#cite_ref-70">^</a></b></span> <span class="reference-text"><cite class="citation web">Krishnan, co-authored by Mandakini Gahlot,Vidya. <a rel="nofollow" class="external text" href="https://caravanmagazine.in/reportage/drug-deals">"How big pharma and the Indian government are letting millions of patients down"</a>. <i>The Caravan</i><span class="reference-accessdate">. Retrieved <span class="nowrap">July 25,</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=The+Caravan&amp;rft.atitle=How+big+pharma+and+the+Indian+government+are+letting+millions+of+patients+down&amp;rft.aulast=Krishnan&amp;rft.aufirst=co-authored+by+Mandakini+Gahlot%2CVidya&amp;rft_id=https%3A%2F%2Fcaravanmagazine.in%2Freportage%2Fdrug-deals&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-71"><span class="mw-cite-backlink"><b><a href="#cite_ref-71">^</a></b></span> <span class="reference-text"><cite class="citation news">Barmann, Jay. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20200326060714/https://sfist.com/2020/02/06/bay-area-based-gilead-donates-experimental-anti-viral-drug-to-china/">"Bay Area-Based Gilead Sees Potential Legal Conflict With China Over Its Coronavirus Drug"</a>. <i>SFist</i>. Impress Media. Archived from <a rel="nofollow" class="external text" href="https://sfist.com/2020/02/06/bay-area-based-gilead-donates-experimental-anti-viral-drug-to-china/">the original</a> on March 26, 2020<span class="reference-accessdate">. Retrieved <span class="nowrap">March 22,</span> 2020</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=SFist&amp;rft.atitle=Bay+Area-Based+Gilead+Sees+Potential+Legal+Conflict+With+China+Over+Its+Coronavirus+Drug&amp;rft.aulast=Barmann&amp;rft.aufirst=Jay&amp;rft_id=https%3A%2F%2Fsfist.com%2F2020%2F02%2F06%2Fbay-area-based-gilead-donates-experimental-anti-viral-drug-to-china%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-rare-72"><span class="mw-cite-backlink">^ <a href="#cite_ref-rare_72-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-rare_72-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation news">Lupkin, Sydney (March 24, 2020). <a rel="nofollow" class="external text" href="https://www.npr.org/sections/health-shots/2020/03/24/821035311/fda-grants-experimental-coronavirus-drug-benefits-for-rare-disease-treatments">"FDA Grants Experimental Coronavirus Drug Benefits For Rare Disease Treatments"</a>. <i>NPR</i><span class="reference-accessdate">. Retrieved <span class="nowrap">March 24,</span> 2020</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=NPR&amp;rft.atitle=FDA+Grants+Experimental+Coronavirus+Drug+Benefits+For+Rare+Disease+Treatments&amp;rft.date=2020-03-24&amp;rft.aulast=Lupkin&amp;rft.aufirst=Sydney&amp;rft_id=https%3A%2F%2Fwww.npr.org%2Fsections%2Fhealth-shots%2F2020%2F03%2F24%2F821035311%2Ffda-grants-experimental-coronavirus-drug-benefits-for-rare-disease-treatments&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-grants-73"><span class="mw-cite-backlink">^ <a href="#cite_ref-grants_73-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-grants_73-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-grants_73-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><cite class="citation news">Conley, Julia (March 24, 2020). <a rel="nofollow" class="external text" href="https://www.commondreams.org/news/2020/03/24/massive-scandal-trump-fda-grants-drug-company-exclusive-claim-promising-coronavirus">"<span class="cs1-kern-left">'</span>This Is a Massive Scandal': Trump FDA Grants Drug Company Exclusive Claim on Promising Coronavirus Drug"</a>. <i>Common Dreams</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Common+Dreams&amp;rft.atitle=%27This+Is+a+Massive+Scandal%27%3A+Trump+FDA+Grants+Drug+Company+Exclusive+Claim+on+Promising+Coronavirus+Drug&amp;rft.date=2020-03-24&amp;rft.aulast=Conley&amp;rft.aufirst=Julia&amp;rft_id=https%3A%2F%2Fwww.commondreams.org%2Fnews%2F2020%2F03%2F24%2Fmassive-scandal-trump-fda-grants-drug-company-exclusive-claim-promising-coronavirus&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-74"><span class="mw-cite-backlink"><b><a href="#cite_ref-74">^</a></b></span> <span class="reference-text"><cite class="citation news">Lawson, Alex (March 25, 2020). <a rel="nofollow" class="external text" href="https://www.commondreams.org/views/2020/03/25/dont-let-big-pharma-make-killing-profiteering-covid-19-treatments">"Don't Let Big Pharma Make a Killing by Profiteering Off COVID-19 Treatments"</a>. <i>Common Dreams</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Common+Dreams&amp;rft.atitle=Don%27t+Let+Big+Pharma+Make+a+Killing+by+Profiteering+Off+COVID-19+Treatments&amp;rft.date=2020-03-25&amp;rft.aulast=Lawson&amp;rft.aufirst=Alex&amp;rft_id=https%3A%2F%2Fwww.commondreams.org%2Fviews%2F2020%2F03%2F25%2Fdont-let-big-pharma-make-killing-profiteering-covid-19-treatments&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-75"><span class="mw-cite-backlink"><b><a href="#cite_ref-75">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.msf.org/no-profiteering-covid-19-drugs-and-vaccines-says-msf">"No profiteering on COVID-19 drugs and vaccines, says MSF"</a>. <i>Médecins Sans Frontières (MSF) International</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=M%C3%A9decins+Sans+Fronti%C3%A8res+%28MSF%29+International&amp;rft.atitle=No+profiteering+on+COVID-19+drugs+and+vaccines%2C+says+MSF&amp;rft_id=https%3A%2F%2Fwww.msf.org%2Fno-profiteering-covid-19-drugs-and-vaccines-says-msf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-76"><span class="mw-cite-backlink"><b><a href="#cite_ref-76">^</a></b></span> <span class="reference-text"><cite class="citation news">Mazzucato, Mariana; Momenghalibaf, Azzi (March 18, 2020). <a rel="nofollow" class="external text" href="https://www.nytimes.com/2020/03/18/opinion/coronavirus-vaccine-cost.html">"Drug Companies Will Make a Killing From Coronavirus"</a>. <i>The New York Times</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+New+York+Times&amp;rft.atitle=Drug+Companies+Will+Make+a+Killing+From+Coronavirus&amp;rft.date=2020-03-18&amp;rft.aulast=Mazzucato&amp;rft.aufirst=Mariana&amp;rft.au=Momenghalibaf%2C+Azzi&amp;rft_id=https%3A%2F%2Fwww.nytimes.com%2F2020%2F03%2F18%2Fopinion%2Fcoronavirus-vaccine-cost.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AGilead+Sciences" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
</ol></div>
</section><h2 class="section-heading" onclick="javascript:mfTempOpenSection(4)"><div class="mw-ui-icon mw-ui-icon-element indicator mw-ui-icon-small mw-ui-icon-flush-left"></div><span class="mw-headline" id="External_links">External links</span><span class="mw-editsection"><a href="/w/index.php?title=Gilead_Sciences&amp;action=edit&amp;section=13" title="Edit section: External links" data-section="13" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h2><section class="mf-section-4 collapsible-block" id="mf-section-4">
<p><a href="/wiki/File:Commons-logo.svg" class="image"><noscript><img alt="" src="//upload.wikimedia.org/wikipedia/en/thumb/4/4a/Commons-logo.svg/12px-Commons-logo.svg.png" decoding="async" width="12" height="16" class="noviewer" data-file-width="1024" data-file-height="1376"></noscript><span class="lazy-image-placeholder" style="width: 12px;height: 16px;" data-src="//upload.wikimedia.org/wikipedia/en/thumb/4/4a/Commons-logo.svg/12px-Commons-logo.svg.png" data-alt="" data-width="12" data-height="16" data-srcset="//upload.wikimedia.org/wikipedia/en/thumb/4/4a/Commons-logo.svg/18px-Commons-logo.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/4/4a/Commons-logo.svg/24px-Commons-logo.svg.png 2x" data-class="noviewer"> </span></a> Media related to <a href="https://commons.wikimedia.org/wiki/Category:Gilead_Sciences" class="extiw" title="commons:Category:Gilead Sciences"><span style="">Gilead Sciences</span></a> at Wikimedia Commons
</p>
<ul><li><span class="official-website"><span class="url"><a rel="nofollow" class="external text" href="https://www.gilead.com/">Official website</a></span></span> <a href="https://www.wikidata.org/wiki/Q663596#P856" title="Edit this at Wikidata"><noscript><img alt="Edit this at Wikidata" src="//upload.wikimedia.org/wikipedia/en/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/10px-OOjs_UI_icon_edit-ltr-progressive.svg.png" decoding="async" width="10" height="10" style="vertical-align: text-top" data-file-width="20" data-file-height="20"></noscript><span class="lazy-image-placeholder" style="width: 10px;height: 10px;" data-src="//upload.wikimedia.org/wikipedia/en/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/10px-OOjs_UI_icon_edit-ltr-progressive.svg.png" data-alt="Edit this at Wikidata" data-width="10" data-height="10" data-srcset="//upload.wikimedia.org/wikipedia/en/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/15px-OOjs_UI_icon_edit-ltr-progressive.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/20px-OOjs_UI_icon_edit-ltr-progressive.svg.png 2x"> </span></a></li>
<li>Business data for Gilead Sciences: <div class="hlist hlist-separated inline"><ul><li><a rel="nofollow" class="external text" href="https://www.google.com/finance?q=GILD">Google Finance</a></li><li><a rel="nofollow" class="external text" href="https://finance.yahoo.com/q?s=GILD">Yahoo! Finance</a></li><li><a rel="nofollow" class="external text" href="https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&amp;CIK=GILD">SEC filings</a></li></ul></div></li></ul>






</section></div><noscript><img src="//en.wikipedia.org/wiki/Special:CentralAutoLogin/start?type=1x1&amp;mobile=1" alt="" title="" width="1" height="1" style="border: none; position: absolute;" /></noscript></div><div class="printfooter">
Retrieved from "<a dir="ltr" href="https://en.wikipedia.org/w/index.php?title=Gilead_Sciences&amp;oldid=951568940">https://en.wikipedia.org/w/index.php?title=Gilead_Sciences&amp;oldid=951568940</a>"</div>
</div>
			<div class="post-content" id="page-secondary-actions">
			
			</div>
		</main>
		<footer class="minerva-footer">
		<div class="last-modified-bar">
	<div class="post-content last-modified-bar__content">
		<span class="last-modified-bar__icon mw-ui-icon mw-ui-icon-mw-ui-icon-small mw-ui-icon-wikimedia-history-base20 "></span>
		<a class="last-modified-bar__text" href="/wiki/Special:History/Gilead_Sciences"
				data-user-name="White whirlwind"
				data-user-gender="male"
				data-timestamp="1587153822">
				<span>Last edited on 17 April 2020, at 20:03</span>
		</a>
		<span class="mw-ui-icon mw-ui-icon-small mw-ui-icon-mf-expand-gray mf-mw-ui-icon-rotate-anti-clockwise indicator"></span>
	</div>
</div>

		<div class="post-content footer-content">
			<div id='mw-data-after-content'>
	<div class="read-more-container"></div>
</div>

			<h2><img src="/static/images/mobile/copyright/wikipedia-wordmark-en.svg" width="116" height="18" alt="Wikipedia"/></h2>
			<div class="license">Content is available under <a class="external" rel="nofollow" href="https://creativecommons.org/licenses/by-sa/3.0/">CC BY-SA 3.0</a> unless otherwise noted.</div>
			<ul class="footer-places hlist hlist-separated">
				<li id="footer-places-terms-use"><a href="//m.wikimediafoundation.org/wiki/Terms_of_Use">Terms of Use</a></li><li id="footer-places-privacy"><a href="https://foundation.wikimedia.org/wiki/Privacy_policy" class="extiw" title="wmf:Privacy policy">Privacy</a></li><li id="footer-places-desktop-toggle"><a id="mw-mf-display-toggle" href="//en.wikipedia.org/w/index.php?title=Gilead_Sciences&amp;mobileaction=toggle_view_desktop">Desktop</a></li>
			</ul>
		</div>
		</footer>
	</div>
</div>
<div class="mw-notification-area" data-mw="interface"></div>
<!-- v:8.3.0 -->

<script>(RLQ=window.RLQ||[]).push(function(){mw.config.set({"wgPageParseReport":{"limitreport":{"cputime":"1.260","walltime":"1.730","ppvisitednodes":{"value":6161,"limit":1000000},"postexpandincludesize":{"value":264253,"limit":2097152},"templateargumentsize":{"value":10153,"limit":2097152},"expansiondepth":{"value":15,"limit":40},"expensivefunctioncount":{"value":9,"limit":500},"unstrip-depth":{"value":1,"limit":20},"unstrip-size":{"value":263976,"limit":5000000},"entityaccesscount":{"value":5,"limit":400},"timingprofile":["100.00% 1540.167      1 -total"," 47.90%  737.713      1 Template:Reflist"," 18.74%  288.593      2 Template:Infobox"," 18.05%  277.967      1 Template:Infobox_company"," 16.66%  256.584     39 Template:Cite_web"," 15.15%  233.264      4 Template:Cite_journal","  7.96%  122.616     25 Template:Cite_news","  6.26%   96.474      8 Template:Wikidata","  5.69%   87.597      1 Template:Br_separated_entries","  4.83%   74.356      1 Template:CladeR"]},"scribunto":{"limitreport-timeusage":{"value":"0.718","limit":"10.000"},"limitreport-memusage":{"value":10713575,"limit":52428800}},"cachereport":{"origin":"mw1265","timestamp":"20200417200344","ttl":86400,"transientcontent":true}}});});</script>
<script type="application/ld+json">{"@context":"https:\/\/schema.org","@type":"Article","name":"Gilead Sciences","url":"https:\/\/en.wikipedia.org\/wiki\/Gilead_Sciences","sameAs":"http:\/\/www.wikidata.org\/entity\/Q663596","mainEntity":"http:\/\/www.wikidata.org\/entity\/Q663596","author":{"@type":"Organization","name":"Contributors to Wikimedia projects"},"publisher":{"@type":"Organization","name":"Wikimedia Foundation, Inc.","logo":{"@type":"ImageObject","url":"https:\/\/www.wikimedia.org\/static\/images\/wmf-hor-googpub.png"}},"datePublished":"2004-09-12T10:21:59Z","dateModified":"2020-04-17T20:03:42Z","headline":"American company"}</script><script>(window.NORLQ=window.NORLQ||[]).push(function(){var ns,i,p,img;ns=document.getElementsByTagName('noscript');for(i=0;i<ns.length;i++){p=ns[i].nextSibling;if(p&&p.className&&p.className.indexOf('lazy-image-placeholder')>-1){img=document.createElement('img');img.setAttribute('src',p.getAttribute('data-src'));img.setAttribute('width',p.getAttribute('data-width'));img.setAttribute('height',p.getAttribute('data-height'));img.setAttribute('alt',p.getAttribute('data-alt'));p.parentNode.replaceChild(img,p);}}});</script>
<script>(RLQ=window.RLQ||[]).push(function(){mw.config.set({"wgBackendResponseTime":154,"wgHostname":"mw1329"});});</script>		</body>
		</html>
		